CREMA TRATTAMENTO PSORIASI OFFERTA -50% !

Home Blog Page 12

Psorilax:commenti |crema lenitiva per psoriasi

0

Psorilax: prezzo, funziona, recensioni, opinioni, ingredienti

BRUXELLES, 20 febbraio 2020 / PRNewswire / – 7:00 (CET) – informazioni regolamentate – “data-reagente =” 12 “>BRUXELLES, 20 febbraio 2020 / PRNewswire / – 7:00 (CET) – informazioni regolamentate –

  • I ricavi hanno raggiunto € 4,9 miliardi (+ 6%, + 7% CER(1)) le vendite nette sono aumentate a 4,7 miliardi di euro (+ 6%)
  • Redditività sottostante (rEBITDA(2)) è stato di 1,4 miliardi di euro (+ 2%, + 11% CER) o del 29,1% delle entrate
  • Aggiornamento R&S: bimekizumab con tre risultati positivi di Fase 3 nella psoriasi e iniziato un nuovo programma di Fase 3 nell'idradenite suppurativa; Cimzia® con approvazioni in Cina e Giappone
  • Previsioni finanziarie per il 2020: le entrate dovrebbero raggiungere € 5,05 – 5,15 miliardi,
    REBITDA(2) 28 – 29% delle entrate, core EPS(3) di € 4,80 – 5,20 previsto
  • Nuova guida alle vendite di punta per Cimzia® 2,0 miliardi di euro entro il 2024 e per Vimpat® 1,5 miliardi di euro entro il 2022
  • Nuova composizione del comitato esecutivo di UCB nel 2020

Jean-Christophe Tellier, CEO UCB. “In base alla nostra promettente pipeline in fase avanzata e all'acquisizione di Ra Pharma in sospeso, potremmo potenzialmente lanciare fino a 7 prodotti entro il 2025 per creare valore per il paziente per popolazioni specifiche ora e in futuro. Inoltre, ci concentriamo su quattro aree di sostenibilità che sono fondamentali al nostro successo a lungo termine e al nostro contributo alla società. “” data -eagid = “21”> “Il 2019 è stato un anno di forte crescita e crescita. Pertanto, abbiamo aggiornato la guida alle vendite di punta per Cimzia® e Vimpat® e continuiamo ad accelerare i nostri investimenti in futuri fattori di crescita “, ha affermato Jean-Christophe Tellier, CEO UCB. “In base alla nostra promettente pipeline in fase avanzata e all'acquisizione di Ra Pharma in sospeso, potremmo potenzialmente lanciare fino a 7 prodotti entro il 2025 per creare valore per il paziente per popolazioni specifiche ora e in futuro. Inoltre, ci concentriamo su quattro aree di sostenibilità che sono fondamentali al nostro successo a lungo termine e al nostro contributo alla società “.

Il Consiglio di amministrazione di UCB propone un dividendo di € 1,24 per azione (lordo), + 2%.

Gennaio 2020, è iniziato lo studio di fase 3 su pazienti con trombocitopenia immunitaria (ITP), i primi risultati attesi sono attesi in H 2 2022. “data-reagid =” 29 “> In Gennaio 2020, è iniziato lo studio di fase 3 su pazienti con trombocitopenia immunitaria (ITP), i primi risultati attesi sono attesi in H 2 2022.

Maggio 2019. “data-reactionid =” 32 “> A dicembre è stato lanciato UCB Nayzilam® (midazolam) Spray nasale CIV, il primo e unico trattamento di salvataggio nasale per i gruppi epilettici negli Stati Uniti Nayzilam® spray nasale è stato approvato negli Stati Uniti a Maggio 2019.

Cina.
A dicembre, Cimzia® è stato approvato per il trattamento della psoriasi e dell'artrite psoriasica in Giappone. “data-reactionid =” 33 “>Immunologia
Nel mese di luglio, Cimzia® (certolizumab pegol) è stato approvato in associazione con metotrexato per il trattamento dell'artrite reumatoide attiva da moderata a grave in pazienti adulti in Cina.
A dicembre, Cimzia® è stato approvato per il trattamento della psoriasi e dell'artrite psoriasica in Giappone.

  • Nel mese di ottobre, lo studio BE VIVID, che valuta l'efficacia e la sicurezza di bimekizumab negli adulti con psoriasi a placche cronica da moderata a grave ha raggiunto tutti gli endpoint primari e secondari, compresa un'efficacia significativamente maggiore rispetto a ustekinumab.
  • A novembre, lo studio BE READY, che valuta l'efficacia e la sicurezza di bimekizumab rispetto al placebo negli adulti con psoriasi a placche cronica da moderata a grave, hanno incontrato tutti gli endpoint primari e secondari classificati.
  • A dicembre, lo studio SIA SICURO, a confronto bimekizumab per adalimumab per il trattamento di adulti con psoriasi a placche da moderata a grave, ha soddisfatto tutti gli endpoint secondari e classificati, ottenendo un'efficacia significativamente maggiore rispetto a adalimumab.
  • Giappone, gli Stati Uniti., Corea del Sud, Canada e Australia nonché nell'UE. “data -eagid =” 41 “>Evenity® (romosozumab) è ora approvato in Giappone, gli Stati Uniti., Corea del Sud, Canada e Australia così come nell'UE.

    In ottobre, a seguito della procedura di riesame, il comitato per i medicinali per uso umano (CHMP) dell'Agenzia europea per i medicinali (EMA) ha adottato un parere positivo raccomandando l'autorizzazione all'immissione in commercio.

    La storia continua

    Europa, Le vendite nette di Keppra® sono state influenzate da un adeguamento locale degli sconti una tantum nella prima metà del 2019 “data-reazioni” = “53”>Keppra® (Levetiracetam) per l'epilessia, ha riportato un fatturato netto di 770 milioni di euro, che riflette sia il marchio forte e affidabile che la maturità del prodotto. Negli Stati Uniti le vendite nette sono state influenzate dalla concorrenza generica. Nel Europa, Le vendite nette di Keppra® sono state influenzate da un adeguamento locale degli sconti una tantum nella prima metà del 2019

    Europa sono stati quasi compensati dalla buona crescita dei mercati internazionali. “data -eagid =” 55 “>Neupro® (Rotigotina), la patch per il morbo di Parkinson, ha mostrato una leggera riduzione delle vendite nette a 319 milioni di euro. Riduzioni minori negli Stati Uniti, dovute all'ambiente di mercato generico – e Europa sono stati quasi compensati da una buona crescita nei mercati internazionali.

    Germania e il supplemento di ferro Niferex® nel primo trimestre del 2019, e prima che le 'coperture designate riclassificate nelle vendite nette' fossero cresciute del + 13% (+ 9% CER). Questa crescita è stata trainata dalla continua forte performance positiva dei prodotti core di UCB.
    Le entrate e le commissioni delle royalties sono diminuite a € 78 milioni da € 92 milioni. Le altre entrate sono aumentate a € 155 milioni dopo € 128 milioni. “Data-reazioni =” 57 “> Nel 2019, entrate e vendite nette aumentato del 6% (+ 7% CER) a 4 913 milioni di euro e rispettivamente a 4 680 milioni di euro (+ 6%; + 7% CER). Le vendite nette prima delle “coperture designate riclassificate in vendite nette” sono aumentate dell'11% (+ 7% CER) a 4 784 milioni di euro. Aggiustato per cessioni nel 2018, principalmente “Innere Medizin” /Germania e il supplemento di ferro Niferex® nel primo trimestre del 2019, e prima che le 'coperture designate riclassificate nelle vendite nette' fossero cresciute del + 13% (+ 9% CER). Questa crescita è stata trainata dalla continua forte performance positiva dei prodotti core di UCB.
    Le entrate e le commissioni delle royalties sono diminuite a € 78 milioni da € 92 milioni. Gli altri ricavi sono aumentati a € 155 milioni dopo € 128 milioni.

    Europa e nella spondiloartrite assiale non radiografica attiva (nr-axSpA) negli Stati Uniti, nonché i preparativi per il lancio di Evenity® nel Europa, Spese di ricerca e sviluppo superiori del 10% di € & nbsp; 1 & nbsp; 272 & nbsp; milioni – trainate da maggiori investimenti in R & amp; D e risultanti in un rapporto di R & amp; D del 26% nel 2019 dopo il 25% nel 2018 e dell'8% in più in generale e amministrativo spese per € 195 milioni, principalmente in relazione al nuovo modello organizzativo implementato nel 2019. Gli altri ricavi operativi sono stati € 48 milioni dopo spese di € 24 milioni nel 2018. I ricavi sono composti da contributi agli investimenti, utili su cessioni , liberazione di accantonamenti e entrate derivanti dalla collaborazione con Amgen in relazione a Evenity®. Ciò ha comportato un rapporto spese operative (in relazione ai ricavi) del 51% dopo il 50% nel 2018. “data-reazioni” = “59”>Spese operative ha raggiunto 2 527 milioni di euro (+ 9%; + 6% CER) riflettendo un aumento del 15% delle spese di marketing e vendita di 1 108 milioni di euro – guidato dal lancio di Cimzia® nella psoriasi negli Stati Uniti e Europa e nella spondiloartrite assiale non radiografica attiva (nr-axSpA) negli Stati Uniti, nonché i preparativi per il lancio di Evenity® nel Europa, Il 10% in più di spese di ricerca e sviluppo di 1 272 milioni di euro – trainati da maggiori investimenti in ricerca e sviluppo e risultante in un rapporto di ricerca e sviluppo del 26% nel 2019 dopo il 25% nel 2018 e 8% in più di spese generali e amministrative di 195 milioni di euro, principalmente connessione con il nuovo modello organizzativo implementato nel 2019. Gli altri ricavi operativi sono stati pari a 48 milioni di euro dopo spese di 24 milioni di euro nel 2018. I proventi sono composti da contributi agli investimenti, utili da cessione, liberazione di accantonamenti e proventi derivanti dalla collaborazione con Amgen in relazione con uniformità®. Ciò ha comportato un rapporto spese operative (in relazione ai ricavi) del 51% dopo il 50% nel 2018.

    Sei anni consecutivi di crescita hanno sottolineato nel tempo le solide prestazioni di UCB. UCB è pronta ad accelerare ulteriormente e ad espandersi per soddisfare le sue ambizioni di valore per il paziente, potenzialmente lanciando sei o sette nuovi prodotti entro il 2025.

    Jean-Christophe Tellier, CEO di UCB “data -eagid =” 70 “>” Per supportare le nostre ambizioni, abbiamo evoluto la nostra organizzazione e i nostri modi di lavorare per assicurarci di diventare più agili e collaborare più trasversalmente all'interno della nostra organizzazione. Riteniamo che questa organizzazione evoluta aumenterà la nostra chiarezza operativa ed efficienza e ci preparerà per lanci incentrati sul valore per il paziente “, ha affermato Jean-Christophe Tellier, CEO di UCB

    Questa evoluzione si riflette nella nuova composizione del Comitato Esecutivo UCB che è diventato più piccolo, con ruoli più trasversali tra le imprese e le regioni e con una maggiore attenzione alle aree di attività principali dell'azienda.

    1o febbraio 2020 la nuova composizione del Comitato Esecutivo di UCB è la seguente: “data -eagid =” 72 “> Da 1o febbraio 2020 la nuova composizione del Comitato esecutivo di UCB è la seguente:

    • Jean-Christophe Tellier, Amministratore delegato
    • Emmanuel Caeymaex, Vicepresidente esecutivo per le soluzioni immunologiche e capo degli Stati Uniti
    • Jean-Luc Fleurial, Vicepresidente esecutivo e direttore delle risorse umane
    • Iris Löw-Friedrich, Vicepresidente esecutivo e Chief Medical Officer
    • Kirsten Lund-Jurgensen, Vicepresidente esecutivo, Soluzioni di approvvigionamento e tecnologia
    • Dhaval Patel, Vicepresidente esecutivo e Direttore scientifico
    • Bill Silbey, Vicepresidente esecutivo e consigliere generale
    • Detlef Thielgen, Vicepresidente esecutivo, Direttore finanziario e Sviluppo aziendale
    • Charl van Zyl, Executive Vice President Neurology Solutions e Head of EU / International

    Alexander Moscho, Pascale Richetta, Bharat Tewarie e Jeff Wren hanno lasciato il Comitato Esecutivo e UCB è molto grato per i loro contributi passati. Bill Silbey e Kirsten Lund-Jurgensen è entrato a far parte del Comitato esecutivo nel 2019.
    Inoltre, UCB ha annunciato in Luglio 2019 che il Chief Financial Officer dell'azienda, Detlef Thielgen, uscirà da UCB nel primo semestre 2020. È in corso la ricerca di un successore. “data -eagid =” 83 “>Alexander Moscho, Pascale Richetta, Bharat Tewarie e Jeff Wren hanno lasciato il Comitato Esecutivo e UCB è molto grato per i loro contributi passati. Bill Silbey e Kirsten Lund-Jurgensen è entrato a far parte del Comitato esecutivo nel 2019.
    Inoltre, UCB ha annunciato in Luglio 2019 che il Chief Financial Officer dell'azienda, Detlef Thielgen, uscirà da UCB nel primo semestre 2020. È in corso la ricerca di un successore.

    https://www.ucb.com/investors/UCB-Governance#book-CMP_B_55790“data -eagid =” 84 “> Ulteriori informazioni sul Comitato esecutivo di UCB sono disponibili sul sito Web di UCB: https://www.ucb.com/investors/UCB-Governance#book-CMP_B_55790

    http://www.ucb.com/investors/Download-center& nbsp; “data -eagid =” 85 “> Trova i rapporti finanziari FY sul sito Web UCB: http://www.ucb.com/investors/Download-center

    Oggi UCB ospiterà una teleconferenza / webcast video alle 08.00 (EST) / 13.00 (GMT) / 14.00 (CET).

    https://www.ucb.com/investors/UCB-financials/Full-year-financial-results“data -eagid =” 87 “> I dettagli sono disponibili su https://www.ucb.com/investors/UCB-financials/Full-year-financial-results

    Bruxelles, Belgio (www.ucb.com) è una società biofarmaceutica globale focalizzata sulla scoperta e lo sviluppo di farmaci e soluzioni innovativi per trasformare la vita delle persone che vivono con gravi malattie del sistema immunitario o del sistema nervoso centrale. Con oltre 7 persone in circa 40 paesi, la società ha generato ricavi per € 4,9 miliardi nel 2019. UCB è quotata su Euronext Bruxelles (simbolo: UCB). Seguiteci su Twitter: @UCB_news “data -eagid =” 88 “>Informazioni su UCB
    UCB, Bruxelles, Belgio (www.ucb.com) è una società biofarmaceutica globale focalizzata sulla scoperta e lo sviluppo di farmaci e soluzioni innovativi per trasformare la vita delle persone che vivono con gravi malattie del sistema immunitario o del sistema nervoso centrale. Con oltre 7 600 persone in circa 40 paesi, la società ha generato ricavi per € 4,9 miliardi nel 2019. UCB è quotata su Euronext Bruxelles (simbolo: UCB). Seguiteci su Twitter: @UCB_news

    Given these uncertainties, you should not place undue reliance on any of such forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labelling in any market, or at any particular time, nor can there be any guarantee that such products will be or will continue to be commercially successful in the future.

    UCB is providing this information, including forward-looking statements, only as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.

    Additionally, information contained in this document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction.

    (1) CER = constant exchange rates

    (3) Core EPS = core earnings per share

    (4) Due to rounding, some financial data may not add up in the tables.

    (5) Due to rounding, some financial data may not add up in the tables.

    (6) rEBITDA = recurring Earnings Before Interest, Taxes, Depreciation and Amortization charges

    http://www.prnewswire.com/news-releases/ucb-full-year-report-2019-301007945.html” data-reactid=”111″>View original content:http://www.prnewswire.com/news-releases/ucb-full-year-report-2019-301007945.html

    SOURCE UCB

    Psorilax:Per i ragazzi |crema aloe psoriasi recensioni

    0

    Psorilax: prezzo, funziona, recensioni, opinioni, come si usa

    Pune, 20 febbraio 2020 (GLOBE NEWSWIRE) – Il globale Mercato della fecondazione in vitro (FIV) si prevede che le dimensioni raggiungeranno i 36,39 miliardi di USD entro il 2026, con un CAGR del 10,1% entro il 2026. Ciò è attribuibile ai crescenti casi di infertilità tra le persone in tutto il mondo. Questo è più comune nei maschi che nelle femmine. Il valore di mercato è stato di 16,89 miliardi di USD nel 2018. La fecondazione in vitro è un processo di fecondazione in cui lo sperma e le uova vengono recuperati come campione e combinati manualmente nei laboratori. Vari studi dimostrano che quasi mezzo milione di bambini sono nati da questo processo o da altri processi riproduttivi di aiuto. Tali fattori sono responsabili della crescita del mercato della fecondazione in vitro.

    Rapporto più recente di Fortune Business Insights ™, intitolato, “Dimensione del mercato della fecondazione in vitro (IVF), analisi delle quote e del settore, per tipo (IVF convenzionale e IVF con ICSI), per procedura (non donatore fresco, non donatore congelato, donatore fresco e donatore congelato), per fine Utente (ospedali e cliniche della fertilità) e previsioni regionali, 2019-2026 ” fornisce una panoramica a 360 gradi del mercato e dei suoi parametri. Questi includono fattori di crescita, restrizioni, sfide e opportunità. Il rapporto fornisce anche una segmentazione dettagliata del mercato con cifre di mercato come base e previsioni e anche i tassi di crescita annuali composti (CAGR). Oltre a ciò, il rapporto fornisce spunti interessanti sul mercato, sugli sviluppi chiave del settore e sulle altre tendenze del mercato della fecondazione in vitro. Il rapporto è disponibile per la vendita sul sito Web dell'azienda.


    Per ulteriori informazioni nell'analisi di questo rapporto, visitare: https://www.fortunebusinessinsights.com/in-vitro-fertilization-ivf-market-102189


    Adozione e pratica dello stile di vita sedentario per aggiungere slancio alla crescita del mercato

    Al giorno d'oggi, le persone sono più propense agli obiettivi di carriera piuttosto che alla pianificazione familiare, e quindi spesso tendono a optare per le gravidanze tardive. Il numero crescente di tali casi è un fattore trainante del mercato dei fertilizzanti in vitro, come menzionato in precedenza, poiché i casi complicati vengono spesso risolti optando per il trattamento della fecondazione in vitro. Ciò è più comune in nazioni come il Regno Unito, il Giappone e gli Stati Uniti. Inoltre, si prevede che l'aumento del numero di infertilità maschile aumenti l'adozione del trattamento per fecondazione in vitro e quindi acceleri la dimensione del mercato della fecondazione in vitro nei prossimi anni. Oltre a ciò, le politiche di rimborso sostenute dal governo e i programmi di sensibilizzazione stanno aiutando la crescita complessiva del mercato della fecondazione in vitro della regione.

    Gli analisti di Fortune Business Insights ™ hanno affermato che “le spese e i rischi elevati legati al processo di fecondazione in vitro (IVF) e all'iniezione intracitoplasmatica di spermatozoi (ICSI) possono causare ostacoli al reddito complessivo del mercato della fecondazione in vitro”. Tuttavia, fattori come l'aumento dei casi di obesità tra le persone, l'infertilità tra gli uomini, la pratica dello stile di vita sedentario e altri probabilmente creeranno opportunità di crescita redditizia del mercato della fecondazione in vitro nei prossimi anni.

    L'Europa domina il mercato con il numero massimo di casi di trattamento registrati

    L'Europa detiene una quota dominante sul mercato della fecondazione in vitro con un fatturato di 7,57 miliardi di USD generato nell'anno 2018. Ciò è attribuibile all'aumento della prevalenza dell'infertilità e alla crescente popolarità del trattamento per fecondazione in vitro nella regione. Dall'altro lato, il mercato del Nord America assisterà a una crescita costante a causa degli alti costi associati al trattamento ICSI e IVF. Secondo i dati FertilityIQ, 2017, negli Stati Uniti, la spesa media di un paziente sottoposto a un singolo ciclo di fecondazione in vitro è di 22.000 USD. Pertanto, i pazienti negli Stati Uniti viaggiano in altri paesi per il trattamento della fecondazione in vitro citando costi inferiori.


    Richiedi una copia di prova del rapporto di ricerca: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/in-vitro-fertilization-ivf-market-102189


    Le aziende stanno investendo nella costruzione di nuovi centri di fertilità per la generazione di entrate

    Boston IVF, Pelargos IVF e Monash IVF stanno attualmente dominando il mercato. I produttori del mercato della fecondazione in vitro stanno sviluppando nuovi centri con un trattamento efficiente e di alta qualità in località remote per accelerare la propria generazione di entrate e lasciare il segno nella concorrenza sul mercato. Ciò alla fine accelererà la dimensione complessiva del mercato della fecondazione in vitro.

    Significativi sviluppi del settore nel mercato della fecondazione in vitro:

    Maggio 2019 – Gli scienziati di Monash IVF hanno sviluppato un nuovo test di screening dell'embrione per ridurre il rischio di aborto spontaneo al momento del trattamento della fecondazione in vitro.

    Luglio 2019 – L'apertura di un nuovo centro IVF a servizio completo presso l'ufficio Westshore di Tampa, in Florida, è stata annunciata da Shady Grove Fertility. L'obiettivo principale dietro l'apertura di questo centro è quello di offrire opzioni di trattamento della fertilità accessibili e di alta qualità alla popolazione regionale.

    Elenco delle principali società che operano nel mercato della fecondazione in vitro (FIV) includono:

    • Monash IVF
    • Fertilità Ovation
    • Centro IVF Bloom
    • Fertilità di Shady Grove
    • Centro IVF di Bangkok
    • Boston IVF
    • Pelargos IVF
    • RSMC
    • Clinica Group Ambroise Paré
    • Altri fornitori di servizi


    Hai qualche domanda? Chiedi ai nostri esperti: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/in-vitro-fertilization-ivf-market-102189


    Tabella dei contenuti dettagliata:

    • introduzione
      • Ambito di ricerca
      • Segmentazione del mercato
      • Metodologia di ricerca
      • Definizioni e presupposti
    • Sintesi
    • Dinamica del mercato
      • Driver di mercato
      • Vincoli di mercato
      • Opportunità di mercato
    • Informazioni chiave
      • Prevalenza di infertilità, per paese / regione chiave, 2018
      • Numero di procedure IVF, per Paese / regioni chiave, 2018
      • Numero di cliniche di fertilità registrate, per paesi chiave, 2018
      • Scenario di rimborso, per Paese / regione chiave
      • Principali sviluppi del settore, partenariati, fusioni e acquisizioni
    • Analisi di mercato, approfondimenti e previsioni del mercato della fecondazione in vitro globale (IVF), 2015-2026
      • Risultati chiave / Riepilogo
      • Analisi di mercato, approfondimenti e previsioni – per tipo
        • FIV convenzionale
        • FIV con ICSI
      • Analisi di mercato, approfondimenti e previsioni – Per procedura
        • Non donatore fresco
        • Non donatore congelato
        • Donatore fresco
        • Donatore congelato
      • Analisi di mercato, approfondimenti e previsioni – Per utente finale
        • ospedali
        • Cliniche di fertilità
      • Analisi di mercato, approfondimenti e previsioni – Per regione
        • Nord America
        • Europa
        • Asia Pacifico
        • America latina
        • Medio Oriente e Africa

    TOC Continua ….


    Richiesta di personalizzazione: https://www.fortunebusinessinsights.com/enquiry/customization/in-vitro-fertilization-ivf-market-102189


    Dai un'occhiata ai rapporti correlati:

    Mercato della diagnostica in vitro (IVD) Dimensioni, condivisione e analisi del settore, per tipo di prodotto (strumenti, reagenti e materiali di consumo), per tecnica (immunodiagnostica, chimica clinica, diagnostica molecolare, punto di cura, ematologia e altri), per applicazione (malattie infettive, cardiologia, oncologia, gastroenterologia, Altri), per utente finale (laboratori clinici, ospedali, uffici medici, altri) e previsioni regionali, 2019-2026

    Mercato della tecnologia di riproduzione assistita (ART) Analisi delle dimensioni, della quota e del settore, per tecnica (fecondazione in vitro (IVF), fecondazione artificiale (AI-IUI), trasferimento di embrioni congelati (FET) e altri), per procedura (donatore fresco, non donatore fresco, donatore congelato e non donatori congelati), per utente finale (cliniche per la fertilità e ospedali) e previsioni regionali, 2019-2026

    Mercato dei biomarcatori Analisi delle dimensioni, della quota e del settore, per indicazione (oncologia, cardiologia, neurologia e altri), per utente finale (aziende farmaceutiche e biotecnologiche, laboratori di diagnostica e ricerca, ospedali e cliniche specializzate e altri) e previsioni regionali, 2019-2026

    Mercato dei dispositivi per neuroendoscopia Analisi delle dimensioni, della quota e dell'industria, per tipo di prodotto (neuroendoscopi rigidi, neuroendoscopi flessibili), per tipo di applicazione (neuroendoscopia transnasale, neuroendoscopia intraventricolare, neuroendoscopia transcranica), per utente finale (ospedali, cliniche specializzate, altri) e previsioni regionali, 2019-2026

    Mercato di sequenziamento di nuova generazione (NGS) Dimensioni, quote e analisi del settore per tipo (prodotti, strumenti e software, materiali di consumo, servizi), per applicazione (diagnostica, ricerca), per utente finale (istituti di ricerca, strutture sanitarie e centri diagnostici, società farmaceutiche e biotecnologiche, organizzazione di ricerca a contratto) E previsioni regionali, 2019-2026

    Mercato della medicina rigenerativa Dimensioni, quota e analisi del settore per prodotto (terapia cellulare, terapia genica, ingegneria tissutale, plasma ricco di piastrine), applicazione (ortopedia, cura delle ferite, oncologia), canale di distribuzione (ospedali, cliniche) e previsioni regionali, 2019-2026

    Mercato della genomica Dimensioni, condivisione e analisi del settore per tipo (prodotti, servizi), tecnologia (reazione a catena della polimerasi, sequenziamento di prossima generazione, microarray, sequenziamento di Sanger), applicazione (diagnostica, ricerca), utente finale (istituti di ricerca, strutture sanitarie e centri diagnostici , Aziende farmaceutiche e biotecnologiche, organizzazione di ricerca a contratto (CRO)) e previsioni regionali, 2019-2026

    Mercato dei servizi della Contract Research Organization (CRO) Analisi delle dimensioni, della quota e del settore per tipo di servizio (scoperta, pre-clinica, clinica, servizi di laboratorio), per applicazione (oncologia, cardiologia, malattie infettive, disturbi metabolici, altro), per utente finale (aziende farmaceutiche e biotecnologiche, società di dispositivi medici , Istituti accademici e di ricerca, altri) e previsioni regionali 2019-2026

    Mercato dell'immunologia Dimensione, quota e analisi del settore per classe di farmaci (anticorpo monoclonale (mAb), proteine ​​di fusione, immunosoppressori, anticorpi policlonali (pAb), altri), per indicazione di malattia (artrite reumatoide, artrite psoriasica, psoriasi a placche, spondilite anchilosante, malattia infiammatoria intestinale, Profilassi del rifiuto d'organo, altri), per canale distributivo e previsioni regionali 2019-2026

    Mercato immunodiagnostico Dimensioni, quota e analisi del settore per strumenti di prodotto, reagenti e materiali di consumo), per applicazione (oncologia ed endocrinologia, epatite e retrovirus, marker cardiaci, malattie infettive), per utente finale (laboratori clinici, ospedali, uffici medici), per utente finale (Ospedali, cliniche dentali, istituti accademici e di ricerca) e previsioni regionali, 2019-2026

    Mercato Ortobiologico Analisi delle dimensioni, della quota e del settore per tipo di prodotto (viscosupplementi, stimolatori della crescita ossea, matrice ossea demineralizzata, sostituti ossei sintetici, cellule staminali, allotrapianti), per applicazione (fusione spinale, maxillo-facciale e dentale, riparazione di tessuti molli, chirurgia ricostruttiva e di frattura), Per utente finale (ospedali, centri di chirurgia ambulatoriale, cliniche specializzate) e previsioni regionali 2019-2026


    Riguardo a noi:

    Fortune Business Insights ™ offre analisi aziendali esperte e dati accurati, aiutando le organizzazioni di tutte le dimensioni a prendere decisioni tempestive. Adattiamo soluzioni innovative per i nostri clienti, aiutandoli ad affrontare le sfide distinte per le loro attività. Il nostro obiettivo è fornire ai nostri clienti informazioni di mercato olistiche, offrendo una panoramica granulare del mercato in cui operano.

    I nostri report contengono un mix unico di intuizioni tangibili e analisi qualitative per aiutare le aziende a raggiungere una crescita sostenibile. Il nostro team di analisti e consulenti esperti utilizza strumenti e tecniche di ricerca leader del settore per compilare studi di mercato completi, intervallati da dati rilevanti.

    A Fortune Business Insights ™ miriamo a evidenziare le opportunità di crescita più redditizie per i nostri clienti. Pertanto, offriamo raccomandazioni, rendendo più semplice la navigazione tra i cambiamenti tecnologici e di mercato. I nostri servizi di consulenza sono progettati per aiutare le organizzazioni a identificare opportunità nascoste e comprendere le sfide competitive prevalenti.

    Contattaci:
    Fortune Business Insights ™ Pvt. Ltd.
    308, sede suprema,
    Sondaggio n. 36, Baner,
    Autostrada Pune-Bangalore,
    Pune – 411045, Maharashtra, India.
    Telefono:
    Stati Uniti: +1 424253 0390
    Regno Unito: +44 2071 939123
    APAC: +91 744740 1245
    E-mail: sales@fortunebusinessinsights.com
    Fortune Business Insights ™
    LinkedIn | cinguettio | Blog

    Comunicato stampa: https://www.fortunebusinessinsights.com/press-release/in-vitro-fertilization-ivf-market-9606

    Logo principale

    Psorilax:Come sbarazzarsi di |psoriasi crema al cortisone

    0

    Psorilax: prezzo, funziona, recensioni, opinioni, originale

    In Vitro Fertilization (IVF) Market size is prophesized to reach USD 36.39 billion by 2026, with a CAGR 10.1% by 2026. This is attributable to the increasing cases of infertility among people worldwide. This is more common in males than female partners. The market value was USD 16.89 billion in 2018. IVF is a fertilization process wherein sperm and eggs are retrieved as a sample and are combined manually in laboratories. Various studies show that almost half a million babies are born by this process or other assistant reproductive processes. Such factors are responsible for the in vitro fertilization market growth.” data-reactid=”12″>Pune, Feb. 20, 2020 (GLOBE NEWSWIRE) — The global In Vitro Fertilization (IVF) Market size is prophesized to reach USD 36.39 billion by 2026, with a CAGR 10.1% by 2026. This is attributable to the increasing cases of infertility among people worldwide. This is more common in males than female partners. The market value was USD 16.89 billion in 2018. IVF is a fertilization process wherein sperm and eggs are retrieved as a sample and are combined manually in laboratories. Various studies show that almost half a million babies are born by this process or other assistant reproductive processes. Such factors are responsible for the in vitro fertilization market growth.

    Nowadays, people are more inclined towards career goals rather than family planning, and therefore often tend to opt for late pregnancies. The increasing number of such cases is a major in vitro fertilizer market driver, as mentioned earlier, since complicated cases are often resolved by opting for IVF treatment. This is more common in nations such as the UK, Japan, and the U.S. Besides this, the rise in the number of male infertility is anticipated to increase the adoption of IVF treatment and thus accelerate the in vitro fertilization market size in the coming years. Besides this, government-supported reimbursement policies and awareness programs are aiding the overall in vitro fertilization market growth of the region.

    Analysts at Fortune Business Insights™ said” high expenses and risks related to the in vitro fertilization process (IVF) and Intracytoplasmic sperm injection (ICSI) may cause hindrance to the overall in vitro fertilization market revenue”. Nevertheless, factors such as increasing obesity cases among people, infertility among men, the practice of sedentary lifestyle, and others are likely to create lucrative IVF market growth opportunities in the coming years.

    Europe holds a dominant in vitro fertilization market share with a revenue of USD 7.57 billion generated in the year 2018. This is attributable to the rise in the prevalence of infertility and the increasing popularity of IVF treatment in the region. On the other side, the market in North America will witness steady growth on account of the high cost associated with ICSI and IVF treatment. As per the FertilityIQ data, 2017, in the U.S., the average expenditure of a patient undergoing a single IVF cycle is USD 22,000. Thus, patients in the U.S are travelling to other countries for IVF treatment citing lower costs.

    Boston IVF, Pelargos IVF, and Monash IVF are currently dominating the market. In vitro fertilization market manufacturers are developing new centers with efficient and high-quality treatment in remote locations for speeding their own revenue generation and making their mark in the market competition. This will ultimately accelerate the overall IVF market size.

  • Monash IVF
  • Ovation Fertility
  • Bloom IVF Centre
  • Shady Grove Fertility
  • Bangkok IVF center
  • Boston IVF
  • Pelargos IVF
  • RSMC
  • Group Ambroise Paré Clinic
  • Other Service Providers
  • https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/in-vitro-fertilization-ivf-market-102189
    ” data-reactid=”43″>
    Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/in-vitro-fertilization-ivf-market-102189

  • Introduction
    • Research Scope
    • Market Segmentation
    • Research Methodology
    • Definitions and Assumptions
  • Executive Summary
  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Key Insights
    • Prevalence of Infertility, For Key Country/Region, 2018
    • Number of IVF Procedures, For Key Country/Regions, 2018
    • Number of Registered Fertility Clinics, For Key Countries, 2018
    • Reimbursement Scenario, For Key Country/Region
    • Key Industry Developments, Partnerships, Mergers and Acquisition
  • Global In Vitro Fertilization (IVF) Market Analysis, Insights and Forecast, 2015-2026
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Type
      • Conventional IVF
      • IVF with ICSI
    • Market Analysis, Insights and Forecast – By Procedure
      • Fresh Non-donor
      • Frozen Non-donor
      • Fresh Donor
      • Frozen Donor
    • Market Analysis, Insights and Forecast – By End User
      • Hospitals
      • Fertility Clinics
    • Market Analysis, Insights and Forecast – By Region
      • North America
      • Europe
      • Asia Pacific
      • Latin America
      • Middle East & Africa
  • TOC Continued….!
    ” data-reactid=”51″>TOC Continued….!

    https://www.fortunebusinessinsights.com/enquiry/customization/in-vitro-fertilization-ivf-market-102189
    ” data-reactid=”52″>
    Request for Customization: https://www.fortunebusinessinsights.com/enquiry/customization/in-vitro-fertilization-ivf-market-102189

    In-vitro Diagnostics (IVD) Market Size, Share & Industry Analysis, By Product Type (Instruments, Reagents & Consumables), By Technique (Immunodiagnostics, Clinical Chemistry, Molecular Diagnostics, Point of Care, Hematology and Others), By Application (Infectious Diseases, Cardiology, Oncology, Gastroenterology, Others), By End User (Clinical Laboratories, Hospitals, Physicians Offices, Others) and Regional Forecast, 2019 – 2026″ data-reactid=”54″>In-vitro Diagnostics (IVD) Market Size, Share & Industry Analysis, By Product Type (Instruments, Reagents & Consumables), By Technique (Immunodiagnostics, Clinical Chemistry, Molecular Diagnostics, Point of Care, Hematology and Others), By Application (Infectious Diseases, Cardiology, Oncology, Gastroenterology, Others), By End User (Clinical Laboratories, Hospitals, Physicians Offices, Others) and Regional Forecast, 2019 – 2026

    Assisted Reproductive Technology (ART) Market Size, Share & Industry Analysis, By Technique (In-Vitro Fertilization (IVF), Artificial Insemination (AI-IUI), Frozen Embryo Transfer (FET), and Others), By Procedure (Fresh Donor, Fresh Non-donor, Frozen Donor, and Frozen Non-donor), By End User (Fertility Clinics, and Hospitals) and Regional Forecast, 2019-2026″ data-reactid=”55″>Assisted Reproductive Technology (ART) Market Size, Share & Industry Analysis, By Technique (In-Vitro Fertilization (IVF), Artificial Insemination (AI-IUI), Frozen Embryo Transfer (FET), and Others), By Procedure (Fresh Donor, Fresh Non-donor, Frozen Donor, and Frozen Non-donor), By End User (Fertility Clinics, and Hospitals) and Regional Forecast, 2019-2026

    Biomarkers Market Size, Share & Industry Analysis, By Indication (Oncology, Cardiology, Neurology, and Others), By End User (Pharmaceutical & Biotechnology Companies, Diagnostics & Research Laboratories, Hospitals & Specialty Clinics, and Others), and Regional Forecast, 2019-2026″ data-reactid=”56″>Biomarkers Market Size, Share & Industry Analysis, By Indication (Oncology, Cardiology, Neurology, and Others), By End User (Pharmaceutical & Biotechnology Companies, Diagnostics & Research Laboratories, Hospitals & Specialty Clinics, and Others), and Regional Forecast, 2019-2026

    Neuroendoscopy Devices Market Size, Share & Industry Analysis, By Product Type (Rigid Neuroendoscopes, Flexible Neuroendoscopes), By Application Type (Transnasal Neuroendoscopy, Intraventricular Neuroendoscopy, Transcranial Neuroendoscopy), By End User (Hospitals, Specialty Clinics, Others) and Regional Forecast, 2019-2026″ data-reactid=”57″>Neuroendoscopy Devices Market Size, Share & Industry Analysis, By Product Type (Rigid Neuroendoscopes, Flexible Neuroendoscopes), By Application Type (Transnasal Neuroendoscopy, Intraventricular Neuroendoscopy, Transcranial Neuroendoscopy), By End User (Hospitals, Specialty Clinics, Others) and Regional Forecast, 2019-2026

    Next-Generation Sequencing (NGS) Market Size, Share and Industry Analysis By Type (Products, Instruments & Software, Consumables, Services), By Application (Diagnostics, Research), By End User (Research Institutes, Healthcare Facilities & Diagnostic Centres, Pharmaceutical & Biotechnological Companies, Contract Research Organization) & Regional Forecast, 2019 – 2026

    Regenerative Medicine Market Size, Share and Industry Analysis By Product (Cell Therapy, Gene Therapy, Tissue Engineering, Platelet Rich Plasma), By Application (Orthopaedics, Wound Care, Oncology), By Distribution Channel (Hospitals, Clinics) & Regional Forecast, 2019 – 2026″ data-reactid=”58″>Next-Generation Sequencing (NGS) Market Size, Share and Industry Analysis By Type (Products, Instruments & Software, Consumables, Services), By Application (Diagnostics, Research), By End User (Research Institutes, Healthcare Facilities & Diagnostic Centres, Pharmaceutical & Biotechnological Companies, Contract Research Organization) & Regional Forecast, 2019 – 2026

    Regenerative Medicine Market Size, Share and Industry Analysis By Product (Cell Therapy, Gene Therapy, Tissue Engineering, Platelet Rich Plasma), By Application (Orthopaedics, Wound Care, Oncology), By Distribution Channel (Hospitals, Clinics) & Regional Forecast, 2019 – 2026

    Genomics Market Size, Share and Industry Analysis By Type (Products, Services), Technology (Polymerase Chain Reaction, Next-generation Sequencing, Microarray, Sanger Sequencing), Application (Diagnostics, Research), End-User (Research Institutes, Healthcare Facilities & Diagnostic Centers, Pharmaceutical & Biotechnological Companies, Contract Research Organization (CROs)) & Regional Forecast, 2019 – 2026″ data-reactid=”59″>Genomics Market Size, Share and Industry Analysis By Type (Products, Services), Technology (Polymerase Chain Reaction, Next-generation Sequencing, Microarray, Sanger Sequencing), Application (Diagnostics, Research), End-User (Research Institutes, Healthcare Facilities & Diagnostic Centers, Pharmaceutical & Biotechnological Companies, Contract Research Organization (CROs)) & Regional Forecast, 2019 – 2026

    Contract Research Organization (CRO) Services Market Size, Share and Industry Analysis By Service Type (Discovery, Pre-Clinical, Clinical, Laboratory Services), By Application (Oncology, Cardiology, Infectious Disease, Metabolic Disorders, Others), By End User (Pharmaceutical & Biotechnological Companies, Medical Device Companies, Academic & Research Institutes, Others), and Regional Forecast 2019-2026″ data-reactid=”60″>Contract Research Organization (CRO) Services Market Size, Share and Industry Analysis By Service Type (Discovery, Pre-Clinical, Clinical, Laboratory Services), By Application (Oncology, Cardiology, Infectious Disease, Metabolic Disorders, Others), By End User (Pharmaceutical & Biotechnological Companies, Medical Device Companies, Academic & Research Institutes, Others), and Regional Forecast 2019-2026

    Immunology Market Size, Share and Industry Analysis By Drug Class (Monoclonal antibody (mAb), Fusion Proteins, Immunosuppressant, Polyclonal antibody (pAb), Others), By Disease Indication (Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, Prophylaxis of Organ Rejection, Others), By Distribution Channel, and Regional Forecast 2019-2026″ data-reactid=”61″>Immunology Market Size, Share and Industry Analysis By Drug Class (Monoclonal antibody (mAb), Fusion Proteins, Immunosuppressant, Polyclonal antibody (pAb), Others), By Disease Indication (Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, Prophylaxis of Organ Rejection, Others), By Distribution Channel, and Regional Forecast 2019-2026

    Immunodiagnostics Market Size, Share and Industry Analysis By Product Instruments, Reagents & Consumables), By Application (Oncology & Endocrinology, Hepatitis & Retrovirus, Cardiac Markers, Infectious Diseases), By End user (Clinical Laboratories, Hospitals, Physician’s Offices), By End-user(Hospitals, Dental Clinics, Academic & Research Institutes) and Regional Forecast, 2019 – 2026″ data-reactid=”62″>Immunodiagnostics Market Size, Share and Industry Analysis By Product Instruments, Reagents & Consumables), By Application (Oncology & Endocrinology, Hepatitis & Retrovirus, Cardiac Markers, Infectious Diseases), By End user (Clinical Laboratories, Hospitals, Physician’s Offices), By End-user(Hospitals, Dental Clinics, Academic & Research Institutes) and Regional Forecast, 2019 – 2026

    Orthobiologics Market Size, Share and Industry Analysis by Product Type (Viscosupplements, Bone Growth Stimulators, Demineralized Bone Matrix, Synthetic Bone Substitutes, Stem Cells, Allografts), By Application (Spinal Fusion, Maxillofacial & Dental, Soft Tissue Repair, Reconstructive & Fracture Surgery), By End User (Hospitals, Ambulatory Surgical Centers, Speciality Clinics), and Regional Forecast 2019-2026″ data-reactid=”63″>Orthobiologics Market Size, Share and Industry Analysis by Product Type (Viscosupplements, Bone Growth Stimulators, Demineralized Bone Matrix, Synthetic Bone Substitutes, Stem Cells, Allografts), By Application (Spinal Fusion, Maxillofacial & Dental, Soft Tissue Repair, Reconstructive & Fracture Surgery), By End User (Hospitals, Ambulatory Surgical Centers, Speciality Clinics), and Regional Forecast 2019-2026

    Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

    Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

    At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

    Fortune Business Insights™
    LinkedIn | Twitter | Blogs
    ” data-reactid=”68″>Contact Us:
    Fortune Business Insights™ Pvt. Ltd.
    308, Supreme Headquarters,
    Survey No. 36, Baner,
    Pune-Bangalore Highway,
    Pune – 411045, Maharashtra, India.
    Phone:
    US :+1 424 253 0390
    UK : +44 2071 939123
    APAC : +91 744 740 1245
    Email: sales@fortunebusinessinsights.com
    Fortune Business Insights™
    LinkedIn | Twitter | Blogs

    https://www.fortunebusinessinsights.com/press-release/in-vitro-fertilization-ivf-market-9606
    ” data-reactid=”69″>Press Release: https://www.fortunebusinessinsights.com/press-release/in-vitro-fertilization-ivf-market-9606

    Psorilax:Prevenire |crema psoriasi genitale

    0

    Psorilax: prezzo, funziona, recensioni, opinioni, ingredienti

    Pune, 20 febbraio 2020 (GLOBE NEWSWIRE) – Il globale Mercato della fecondazione in vitro (FIV) si prevede che le dimensioni raggiungeranno i 36,39 miliardi di USD entro il 2026, con un CAGR del 10,1% entro il 2026. Ciò è attribuibile ai crescenti casi di infertilità tra le persone in tutto il mondo. Questo è più comune nei maschi che nelle femmine. Il valore di mercato è stato di 16,89 miliardi di USD nel 2018. La fecondazione in vitro è un processo di fecondazione in cui lo sperma e le uova vengono recuperati come campione e combinati manualmente nei laboratori. Vari studi dimostrano che quasi mezzo milione di bambini sono nati da questo processo o da altri processi riproduttivi di aiuto. Tali fattori sono responsabili della crescita del mercato della fecondazione in vitro.

    Rapporto più recente di Fortune Business Insights ™, intitolato, “Dimensioni del mercato della fecondazione in vitro (IVF), analisi delle quote e del settore, per tipo (IVF convenzionale e IVF con ICSI), per procedura (non donatore fresco, non donatore congelato, donatore fresco e donatore congelato), per fine Utente (ospedali e cliniche della fertilità) e previsioni regionali, 2019-2026 ” fornisce una panoramica a 360 gradi del mercato e dei suoi parametri. Questi includono fattori di crescita, restrizioni, sfide e opportunità. Il rapporto fornisce anche una segmentazione dettagliata del mercato con cifre di mercato come base e previsioni e anche i tassi di crescita annuali composti (CAGR). Oltre a ciò, il rapporto fornisce spunti interessanti sul mercato, sugli sviluppi chiave del settore e sulle altre tendenze del mercato della fecondazione in vitro. Il rapporto è disponibile per la vendita sul sito Web dell'azienda.


    Per ulteriori informazioni nell'analisi di questo rapporto, visitare: https://www.fortunebusinessinsights.com/in-vitro-fertilization-ivf-market-102189


    Adozione e pratica dello stile di vita sedentario per aggiungere slancio alla crescita del mercato

    Al giorno d'oggi, le persone sono più propense agli obiettivi di carriera piuttosto che alla pianificazione familiare, e quindi spesso tendono a optare per le gravidanze tardive. Il numero crescente di tali casi è un fattore trainante del mercato dei fertilizzanti in vitro, come menzionato in precedenza, poiché i casi complicati vengono spesso risolti optando per il trattamento della fecondazione in vitro. Ciò è più comune in nazioni come Regno Unito, Giappone e Stati Uniti. Inoltre, si prevede che l'aumento del numero di infertilità maschile aumenti l'adozione del trattamento per fecondazione in vitro e quindi acceleri la dimensione del mercato della fecondazione in vitro nei prossimi anni. Oltre a ciò, le politiche di rimborso sostenute dal governo e i programmi di sensibilizzazione stanno aiutando la crescita complessiva del mercato della fecondazione in vitro della regione.

    Gli analisti di Fortune Business Insights ™ hanno affermato che “le spese e i rischi elevati legati al processo di fecondazione in vitro (IVF) e all'iniezione intracitoplasmatica di spermatozoi (ICSI) possono causare ostacoli al reddito complessivo del mercato della fecondazione in vitro”. Tuttavia, fattori come l'aumento dei casi di obesità tra le persone, l'infertilità tra gli uomini, la pratica dello stile di vita sedentario e altri probabilmente creeranno opportunità di crescita redditizia del mercato della fecondazione in vitro nei prossimi anni.

    L'Europa domina il mercato con il numero massimo di casi di trattamento registrati

    L'Europa detiene una quota dominante sul mercato della fecondazione in vitro con un fatturato di 7,57 miliardi di USD generato nell'anno 2018. Ciò è attribuibile all'aumento della prevalenza dell'infertilità e alla crescente popolarità del trattamento della fecondazione in vitro nella regione. Dall'altro lato, il mercato del Nord America assisterà a una crescita costante a causa degli alti costi associati al trattamento ICSI e IVF. Secondo i dati FertilityIQ, 2017, negli Stati Uniti, la spesa media di un paziente sottoposto a un singolo ciclo di fecondazione in vitro è di 22.000 USD. Pertanto, i pazienti negli Stati Uniti viaggiano in altri paesi per il trattamento della fecondazione in vitro citando costi inferiori.


    Richiedi una copia di prova del rapporto di ricerca: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/in-vitro-fertilization-ivf-market-102189


    Le aziende stanno investendo nella costruzione di nuovi centri di fertilità per la generazione di entrate

    Boston IVF, Pelargos IVF e Monash IVF stanno attualmente dominando il mercato. I produttori del mercato della fecondazione in vitro stanno sviluppando nuovi centri con un trattamento efficiente e di alta qualità in località remote per accelerare la propria generazione di entrate e lasciare il segno nella concorrenza sul mercato. Ciò alla fine accelererà la dimensione complessiva del mercato della fecondazione in vitro.

    Significativi sviluppi del settore nel mercato della fecondazione in vitro:

    Maggio 2019 – Gli scienziati di Monash IVF hanno sviluppato un nuovo test di screening dell'embrione per ridurre il rischio di aborto spontaneo al momento del trattamento della fecondazione in vitro.

    Luglio 2019 – L'apertura di un nuovo centro IVF a servizio completo presso l'ufficio Westshore di Tampa, in Florida, è stata annunciata da Shady Grove Fertility. L'obiettivo principale dietro l'apertura di questo centro è quello di offrire opzioni di trattamento della fertilità accessibili e di alta qualità alla popolazione regionale.

    Elenco delle principali società che operano nel mercato della fecondazione in vitro (FIV) includono:

    • Monash IVF
    • Fertilità Ovation
    • Centro IVF Bloom
    • Fertilità di Shady Grove
    • Centro IVF di Bangkok
    • Boston IVF
    • Pelargos IVF
    • RSMC
    • Clinica Group Ambroise Paré
    • Altri fornitori di servizi


    Hai qualche domanda? Chiedi ai nostri esperti: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/in-vitro-fertilization-ivf-market-102189


    Tabella dei contenuti dettagliata:

    • introduzione
      • Ambito di ricerca
      • Segmentazione del mercato
      • Metodologia di ricerca
      • Definizioni e presupposti
    • Sintesi
    • Dinamica del mercato
      • Driver di mercato
      • Vincoli di mercato
      • Opportunità di mercato
    • Informazioni chiave
      • Prevalenza di infertilità, per paese / regione chiave, 2018
      • Numero di procedure IVF, per Paese / regioni chiave, 2018
      • Numero di cliniche di fertilità registrate, per paesi chiave, 2018
      • Scenario di rimborso, per Paese / regione chiave
      • Principali sviluppi del settore, partenariati, fusioni e acquisizioni
    • Analisi di mercato, approfondimenti e previsioni del mercato della fecondazione in vitro globale (IVF), 2015-2026
      • Risultati chiave / Riepilogo
      • Analisi di mercato, approfondimenti e previsioni – per tipo
        • FIV convenzionale
        • FIV con ICSI
      • Analisi di mercato, approfondimenti e previsioni – Per procedura
        • Non donatore fresco
        • Non donatore congelato
        • Donatore fresco
        • Donatore congelato
      • Analisi di mercato, approfondimenti e previsioni – Per utente finale
        • ospedali
        • Cliniche di fertilità
      • Analisi di mercato, approfondimenti e previsioni – Per regione
        • Nord America
        • Europa
        • Asia Pacifico
        • America latina
        • Medio Oriente e Africa

    TOC Continua ….


    Richiesta di personalizzazione: https://www.fortunebusinessinsights.com/enquiry/customization/in-vitro-fertilization-ivf-market-102189


    Dai un'occhiata ai rapporti correlati:

    Mercato della diagnostica in vitro (IVD) Dimensioni, condivisione e analisi del settore, per tipo di prodotto (strumenti, reagenti e materiali di consumo), per tecnica (immunodiagnostica, chimica clinica, diagnostica molecolare, punto di cura, ematologia e altri), per applicazione (malattie infettive, cardiologia, oncologia, gastroenterologia, Altri), per utente finale (laboratori clinici, ospedali, uffici medici, altri) e previsioni regionali, 2019-2026

    Mercato della tecnologia di riproduzione assistita (ART) Analisi delle dimensioni, della quota e del settore, per tecnica (fecondazione in vitro (IVF), fecondazione artificiale (AI-IUI), trasferimento di embrioni congelati (FET) e altri), per procedura (donatore fresco, non donatore fresco, donatore congelato e non donatori congelati), per utente finale (cliniche per la fertilità e ospedali) e previsioni regionali, 2019-2026

    Mercato dei biomarcatori Analisi delle dimensioni, della quota e del settore, per indicazione (oncologia, cardiologia, neurologia e altri), per utente finale (aziende farmaceutiche e biotecnologiche, laboratori di diagnostica e ricerca, ospedali e cliniche specializzate e altri) e previsioni regionali, 2019-2026

    Mercato dei dispositivi per neuroendoscopia Analisi delle dimensioni, della quota e dell'industria, per tipo di prodotto (neuroendoscopi rigidi, neuroendoscopi flessibili), per tipo di applicazione (neuroendoscopia transnasale, neuroendoscopia intraventricolare, neuroendoscopia transcranica), per utente finale (ospedali, cliniche specializzate, altri) e previsioni regionali, 2019-2026

    Mercato di sequenziamento di nuova generazione (NGS) Dimensioni, quote e analisi del settore per tipo (prodotti, strumenti e software, materiali di consumo, servizi), per applicazione (diagnostica, ricerca), per utente finale (istituti di ricerca, strutture sanitarie e centri diagnostici, società farmaceutiche e biotecnologiche, organizzazione di ricerca a contratto) E previsioni regionali, 2019-2026

    Mercato della medicina rigenerativa Dimensioni, quota e analisi del settore per prodotto (terapia cellulare, terapia genica, ingegneria tissutale, plasma ricco di piastrine), applicazione (ortopedia, cura delle ferite, oncologia), canale di distribuzione (ospedali, cliniche) e previsioni regionali, 2019-2026

    Mercato della genomica Dimensioni, condivisione e analisi del settore per tipo (prodotti, servizi), tecnologia (reazione a catena della polimerasi, sequenziamento di prossima generazione, microarray, sequenziamento di Sanger), applicazione (diagnostica, ricerca), utente finale (istituti di ricerca, strutture sanitarie e centri diagnostici , Aziende farmaceutiche e biotecnologiche, organizzazione di ricerca a contratto (CRO)) e previsioni regionali, 2019-2026

    Mercato dei servizi della Contract Research Organization (CRO) Dimensioni, quote e analisi del settore per tipo di servizio (scoperta, servizi preclinici, clinici, di laboratorio), per applicazione (oncologia, cardiologia, malattie infettive, disturbi metabolici, altro), per utente finale (aziende farmaceutiche e biotecnologiche, società di dispositivi medici , Istituti accademici e di ricerca, altri) e previsioni regionali 2019-2026

    Mercato dell'immunologia Dimensione, quota e analisi del settore per classe di farmaci (anticorpo monoclonale (mAb), proteine ​​di fusione, immunosoppressori, anticorpi policlonali (pAb), altri), per indicazione di malattia (artrite reumatoide, artrite psoriasica, psoriasi a placche, spondilite anchilosante, malattia infiammatoria intestinale, Profilassi del rifiuto d'organo, altri), per canale distributivo e previsioni regionali 2019-2026

    Mercato immunodiagnostico Dimensioni, quota e analisi del settore per strumenti di prodotto, reagenti e materiali di consumo), per applicazione (oncologia ed endocrinologia, epatite e retrovirus, marker cardiaci, malattie infettive), per utente finale (laboratori clinici, ospedali, uffici medici), per utente finale (Ospedali, cliniche dentali, istituti accademici e di ricerca) e previsioni regionali, 2019-2026

    Mercato Ortobiologico Analisi delle dimensioni, della quota e del settore per tipo di prodotto (viscosupplementi, stimolatori della crescita ossea, matrice ossea demineralizzata, sostituti ossei sintetici, cellule staminali, allotrapianti), per applicazione (fusione spinale, maxillo-facciale e dentale, riparazione di tessuti molli, chirurgia ricostruttiva e di frattura), Per utente finale (ospedali, centri di chirurgia ambulatoriale, cliniche specializzate) e previsioni regionali 2019-2026


    Riguardo a noi:

    Fortune Business Insights ™ offre analisi aziendali esperte e dati accurati, aiutando le organizzazioni di tutte le dimensioni a prendere decisioni tempestive. Adattiamo soluzioni innovative per i nostri clienti, aiutandoli ad affrontare le sfide distinte per le loro attività. Il nostro obiettivo è fornire ai nostri clienti informazioni di mercato olistiche, offrendo una panoramica granulare del mercato in cui operano.

    I nostri report contengono un mix unico di intuizioni tangibili e analisi qualitative per aiutare le aziende a raggiungere una crescita sostenibile. Il nostro team di analisti e consulenti esperti utilizza strumenti e tecniche di ricerca leader del settore per compilare studi di mercato completi, intervallati da dati rilevanti.

    A Fortune Business Insights ™ miriamo a evidenziare le opportunità di crescita più redditizie per i nostri clienti. Pertanto, offriamo raccomandazioni, rendendo più semplice la navigazione tra i cambiamenti tecnologici e di mercato. I nostri servizi di consulenza sono progettati per aiutare le organizzazioni a identificare opportunità nascoste e comprendere le sfide competitive prevalenti.

    Contattaci:
    Fortune Business Insights ™ Pvt. Ltd.
    308, sede suprema,
    Sondaggio n. 36, Baner,
    Autostrada Pune-Bangalore,
    Pune – 411045, Maharashtra, India.
    Telefono:
    Stati Uniti: +1 424253 0390
    Regno Unito: +44 2071 939123
    APAC: +91 744740 1245
    E-mail: sales@fortunebusinessinsights.com
    Fortune Business Insights ™
    LinkedIn | cinguettio | Blog

    Comunicato stampa: https://www.fortunebusinessinsights.com/press-release/in-vitro-fertilization-ivf-market-9606

    Psorilax:Coupon |psoriasi crema solare quale scegliere

    0

    Psorilax: prezzo, funziona, recensioni, opinioni, originale

    BRUSSELS, Feb. 20, 2020 /PRNewswire/ — 7:00 (CET) – regulated information –

    • Revenue reached € 4.9 billion (+6%, +7% CER(1)) net sales increased to € 4.7 billion (+6%)
    • Underlying profitability (rEBITDA(2)) was € 1.4 billion (+2%, +11% CER) or 29.1% of revenue
    • R&D update: bimekizumab with three positive Phase 3 results in psoriasis and a new Phase 3 program in hidradenitis suppurativa started; Cimzia® with approvals in China and Japan
    • Financial outlook for 2020: Revenue expected to reach € 5.05 – 5.15 billion,
      rEBITDA(2) 28 – 29% of revenue, Core EPS(3) of € 4.80 – 5.20 expected
    • New peak sales guidance for Cimzia® € 2.0 bn by 2024 and for Vimpat® € 1.5 bn by 2022
    • New Composition of UCB’s Executive Committee in 2020

    “2019 was a year of strong delivery and growth. Hence, we have updated the peak sales guidance for Cimzia® and Vimpat® and we continue to accelerate our investments into future growth drivers,” said Jean-Christophe Tellier, CEO UCB. “Based on our promising late-stage pipeline and the pending Ra Pharma acquisition, we could potentially launch up to 7 products by 2025 to create patient value for specific populations now and into the future. Also, we focus on four sustainability areas that are critical to our long-term success and our contribution to society.”

    Revenue for 2019 reached € 4.9 billion (+6%; +7% at CER). Net sales went up by 6% to € 4.7 billion (+7% CER), driven by the strong double-digit growth of UCB’s key franchises: immunology and epilepsy.

    Underlying profitability (rEBITDA(2) ) reached € 1.4 billion (+2%; +11% CER) with higher net sales overcompensating increased expenses for product launches and product development.

    Profit was to € 817 million of which € 792 million (-1%; +15% CER) is attributable to the UCB shareholders.

    Core EPS(3) were € 5.20 after € 4.78 in 2018.

    The Board of Directors of UCB proposes a dividend of € 1.24 per share (gross), +2%.

    R&D update

    Neurology
    In June, the Phase 3 study started in patients with myasthenia gravis with rozanolixizumab. First headline results are expected in H1 2021.

    In January 2020, the Phase 3 study in patients with immune thrombocytopenia (ITP) started, first headline results are expected in H 2 2022.

    In September, new data from a Phase 1 study indicated that UCB0107 anti-Tau was well tolerated with an acceptable safety profile. UCB aims to initiate an adequate and well controlled study in Q2 2020. UCB0107 is currently being investigated as a potential treatment for patients with tauopathies, initially focusing on progressive supranuclear palsy.

    In October, Keppra® (levetiracetam) was approved, in the U.S., for monotherapy in partial onset seizures. The new indication is intended for the use of Keppra® as mono-therapy in treatment of partial-onset seizures in patients one month of age and older and with an updated labeling to comply with the Pregnancy and Lactation Labeling Rule. An important driver for this submission was adding patient value, especially for pregnant women or women of childbearing age.

    In December, UCB launched Nayzilam® (midazolam) Nasal Spray CIV, the first and only nasal rescue treatment for seizure clusters in the U.S. Nayzilam® nasal spray was approved in the U.S. in May 2019.

    Immunology
    In July, Cimzia® (certolizumab pegol) was approved in combination with methotrexate for the treatment of moderate to severe, active rheumatoid arthritis in adult patients in China.
    In December, Cimzia® was approved for the treatment of psoriasis and psoriatic arthritis in Japan.

    During the course of the fourth quarter 2019, UCB reported positive results for three Phase 3 studies with bimekizumab in psoriasis:

    • In October, the study BE VIVID, evaluating the efficacy and safety of bimekizumab in adults with moderate-to-severe chronic plaque psoriasis met all primary and ranked secondary endpoints, including significantly greater efficacy compared to ustekinumab.
    • In November, the study BE READY, evaluating the efficacy and safety of bimekizumab versus placebo in adults with moderate-to-severe chronic plaque psoriasis, met all primary and ranked secondary endpoints.
    • In December, the study BE SURE, comparing bimekizumab to adalimumab for the treatment of adults with moderate-to-severe plaque psoriasis, met all co-primary and ranked secondary endpoints, achieving significantly greater efficacy than adalimumab.

    UCB plans to submit applications to regulatory authorities for approval of bimekizumab to treat adults with moderate-to-severe plaque psoriasis in mid-2020.

    In addition, based on a positive proof-of-concept study, UCB decided to move into late stage development with bimekizumab in moderate to severe hidradenitis suppurativa (HS), a severe inflammatory skin disease, affecting predominantly women. The Phase 3 program BE HEARD starts in Q1 2020. First headline results are expected in H1 2023.

    Evenity® (romosozumab) is now approved in Japan, the U.S., South Korea, Canada and Australia as well as in the EU.

    In October, following re-examination procedure, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), has adopted a positive opinion recommending Marketing Authorization.

    Evenity® was approved by the EMA in December for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture.

    Net sales break-down by core product(4)

    Immunology

    Cimzia® (certolizumab pegol) for patients living with autoimmune and inflammatory TNF mediated diseases, net sales increased to more than € 1.7 billion, driven by continued, sustainable growth in all regions. Growth is also driven by new patient populations like women of childbearing age and people living with non-radio-graphic axial spondyloarthritis and with psoriasis

    Neurology: UCB’s epilepsy franchise reached net sales of € 2.3 billion, a plus of 12%.

    Vimpat® (lacosamide), with net sales of more than € 1.3 billion, shows continued double-digit strong growth in all regions thanks to reaching more and more people living with epilepsy.

    Keppra® (levetiracetam) for epilepsy, reported net sales of € 770 million, reflecting both, the strong, trusted brand and the maturity of the product. In the U.S. net sales were impacted by generic competition. In Europe, Keppra® net sales were affected by a local, one-time rebate adjustment in the first half 2019

    Briviact® (brivaracetam), reached net sales of € 221 million. This is driven by significant, continuous growth in all regions where Briviact® is now available to patients

    Neupro® (rotigotine), the patch for Parkinson’s disease, showed a slight decrease of net sales to € 319 million. Smaller declines in the U.S. -due to the generic market environment – and Europe were almost compensated by good growth in international markets.

    2019 FY financial highlights(5)

    In 2019, revenue and net sales increased by 6% (+7% CER) to € 4 913 million and to € 4 680 million (+6%; +7% CER) respectively. Net sales before “designated hedging reclassified to net sales” went up by 11% (+7% CER) to €4 784 million. Adjusted for divestitures in 2018, mainly “Innere Medizin”/Germany and the iron supplement Niferex® in Q1 2019, and before ‘designated hedges reclassified to net sales’ growth was +13% (+9% CER). This growth was driven by the continued strong positive performance of UCB’s core products.
    Royalty income and fees decreased to € 78 million from € 92 million. Other revenue increased to € 155 million after € 128 million.

    Gross profit reached € 3 645 million, with a plus of 6% in-line with the net sales growths and reflecting a stable gross margin compared to 2018.

    Operating expenses reached € 2 527 million (+9%; +6% CER) reflecting 15% higher marketing and selling expenses of € 1 108 million – driven by the launch of Cimzia® in psoriasis in the U.S. and Europe and in active non-radiographic axial spondyloarthritis (nr-axSpA) in the U.S. as well as launch preparations for Evenity® in Europe, 10% higher research and development expenses of € 1 272 million – driven by higher R&D investments and resulting in a R&D ratio of 26% in 2019 after 25% in 2018 and 8% higher general and administrative expenses of € 195 million, mainly in connection with the new organization model implemented in 2019. Other operating income was € 48 million after expenses of € 24 million in 2018. The income is composed of investment grants, gain on divestiture, release of provisions and income from the collaboration with Amgen in connection with Evenity®. This resulted in an operating expense ratio (in relation to revenue) of 51% after 50% in 2018.

    Underlying operational profitability – rEBITDA(6) – reached € 1 431 million a plus of 2% (+11% CER) with higher net sales overcompensating increased expenses for product launches and product development. The rEBITDA ratio for 2019 (in % of revenue) reached 29.1%, from 30.2% in 2018.

    Total impairment, restructuring and other income/expenses (formerly called “non-recurring”) were expenses of € 50 million after an income of € 4 million in 2018. In 2019, this includes mainly restructuring expenses, but also legal and litigation costs, partially offset with income resulting from gain on the divestitures. In 2019, UCB strengthened its operating model to ensure maximum agility to meet the growth expectations for the years ahead, hence the restructuring expenses.

    Net financial expenses increased by 15% to € 107 million.

    Income tax expenses were € 146 million compared to € 200 million in 2018. The effective tax rate of 15% is driven by the higher group revenue and the increasing impact of R&D related tax deductions in key countries.

    Profit amounted to € 817 million (after € 823 million), of which € 792 million (after € 800 million) is attributable to UCB shareholders and € 25 million (after € 23 million) to non-controlling interests.

    Core earnings per share, which reflect profit attributable to UCB shareholders, adjusted for the after-tax impact of impairment, restructuring, other operating income/expenses, the financial one-offs, the after-tax contribution from discontinued operations and the net amortization of intangibles linked to sales, reached € 5.20 after € 4.78 based on 187 million weighted average shares outstanding.

    Dividend – The Board of Directors of UCB proposes a dividend of €1.24 per share (gross), +2%.

    Outlook 2020 – For 2020, UCB is aiming for revenues in the range of € 5.05 – 5.15 billion – thanks to the current core product growth and new patient populations being served. UCB will continue to advance its strong development pipeline to offer potential new solutions for patients and complement with external opportunities. Hence, the underlying profitability, rEBITDA6, in the range of 28-29% of revenue will reflect the high R&D investment level. Core earnings per share are therefore expected in the range of € 4.80 – 5.20 based on an average of 187 million shares outstanding. The figures for the outlook 2020 as mentioned are calculated on the same basis as the actual figures for 2019. The 2020 outlook will be updated upon closing of the planned Ra Pharma acquisition.

    New Composition of UCB’s Executive Committee in 2020

    Six consecutive years of growth have underscored UCB’s robust performance over time. UCB is poised to further accelerate and expand to deliver on its Patient Value ambition, potentially launching six or seven new products by 2025.

    “To support our ambition, we evolved our organization and ways of working to ensure we become more agile and collaborate more transversally across our organization. We believe this evolved organization will increase our operational clarity and efficiency, and will set us up for truly patient-value focused launches,” said Jean-Christophe Tellier, CEO of UCB

    This evolution is reflected in the new composition of the UCB Executive Committee which became smaller, with more transversal roles across businesses and regions, and with more focus on the company’s core activity areas.

    Since 1 February 2020 the new composition of the Executive Committee of UCB is as follows:

    • Jean-Christophe Tellier, Chief Executive Officer
    • Emmanuel Caeymaex, Executive Vice President Immunology Solutions & Head of US
    • Jean-Luc Fleurial, Executive Vice President & Chief Human Resources Officer
    • Iris Löw-Friedrich, Executive Vice President & Chief Medical Officer
    • Kirsten Lund-Jurgensen, Executive Vice President, Supply & Technology Solutions
    • Dhaval Patel, Executive Vice President & Chief Scientific Officer
    • Bill Silbey, Executive Vice-President & General Counsel
    • Detlef Thielgen, Executive Vice President, Chief Financial Officer & Corporate Development
    • Charl van Zyl, Executive Vice President Neurology Solutions & Head of EU/International

    Alexander Moscho, Pascale Richetta, Bharat Tewarie and Jeff Wren have left the Executive Committee and UCB is very thankful for their past contributions. Bill Silbey and Kirsten Lund-Jurgensen joined the Executive Committee in 2019.
    Furthermore, UCB announced in July 2019 that the company’s Chief Financial Officer, Detlef Thielgen, will be transitioning out of UCB in H1 2020. A search for a successor is ongoing.

    Further information about UCB’s Executive Committee are available on UCB website: https://www.ucb.com/investors/UCB-Governance#book-CMP_B_55790

    Find the FY financial reports on UCB website: http://www.ucb.com/investors/Download-center

    Today, UCB will host a conference call/video webcast at 08.00 (EST) / 13.00 (GMT) / 14.00 (CET).

    Details are available on https://www.ucb.com/investors/UCB-financials/Full-year-financial-results

    About UCB
    UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 600 people in approximately 40 countries, the company generated revenue of € 4.9 billion in 2019. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news

    Forward looking statements
    This press release contains forward-looking statements including, without limitation, statements containing the words “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to differ materially from those that may be expressed or implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring and retention of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB’ efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB’s products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB’s data and systems.

    Given these uncertainties, you should not place undue reliance on any of such forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labelling in any market, or at any particular time, nor can there be any guarantee that such products will be or will continue to be commercially successful in the future.

    UCB is providing this information, including forward-looking statements, only as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.

    Additionally, information contained in this document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction.

    (1) CER = constant exchange rates

    (2) rEBITDA = recurring Earnings Before Interest, Taxes, Depreciation and Amortization charges

    (3) Core EPS = core earnings per share

    (4) Due to rounding, some financial data may not add up in the tables.

    (5) Due to rounding, some financial data may not add up in the tables.

    (6) rEBITDA = recurring Earnings Before Interest, Taxes, Depreciation and Amortization charges

    SOURCE UCB

    Psorilax:Tutorial gratuito |crema per psoriasi pustolosa

    0

    Psorilax: prezzo, funziona, recensioni, opinioni, quanto costa

    BRUSSELS, Feb. 20, 2020 /PRNewswire/ — 7:00 (CET) – regulated information –

    • Revenue reached € 4.9 billion (+6%, +7% CER(1)) net sales increased to € 4.7 billion (+6%)
    • Underlying profitability (rEBITDA(2)) was € 1.4 billion (+2%, +11% CER) or 29.1% of revenue
    • R&D update: bimekizumab with three positive Phase 3 results in psoriasis and a new Phase 3 program in hidradenitis suppurativa started; Cimzia® with approvals in China and Japan
    • Financial outlook for 2020: Revenue expected to reach € 5.05 – 5.15 billion,
      rEBITDA(2) 28 – 29% of revenue, Core EPS(3) of € 4.80 – 5.20 expected
    • New peak sales guidance for Cimzia® € 2.0 bn by 2024 and for Vimpat® € 1.5 bn by 2022
    • New Composition of UCB’s Executive Committee in 2020

    “2019 was a year of strong delivery and growth. Hence, we have updated the peak sales guidance for Cimzia® and Vimpat® and we continue to accelerate our investments into future growth drivers,” said Jean-Christophe Tellier, CEO UCB. “Based on our promising late-stage pipeline and the pending Ra Pharma acquisition, we could potentially launch up to 7 products by 2025 to create patient value for specific populations now and into the future. Also, we focus on four sustainability areas that are critical to our long-term success and our contribution to society.”

    Revenue for 2019 reached € 4.9 billion (+6%; +7% at CER). Net sales went up by 6% to € 4.7 billion (+7% CER), driven by the strong double-digit growth of UCB’s key franchises: immunology and epilepsy.

    Underlying profitability (rEBITDA(2) ) reached € 1.4 billion (+2%; +11% CER) with higher net sales overcompensating increased expenses for product launches and product development.

    Profit was to € 817 million of which € 792 million (-1%; +15% CER) is attributable to the UCB shareholders.

    Core EPS(3) were € 5.20 after € 4.78 in 2018.

    The Board of Directors of UCB proposes a dividend of € 1.24 per share (gross), +2%.

    R&D update

    Neurology
    In June, the Phase 3 study started in patients with myasthenia gravis with rozanolixizumab. First headline results are expected in H1 2021.

    In January 2020, the Phase 3 study in patients with immune thrombocytopenia (ITP) started, first headline results are expected in H 2 2022.

    In September, new data from a Phase 1 study indicated that UCB0107 anti-Tau was well tolerated with an acceptable safety profile. UCB aims to initiate an adequate and well controlled study in Q2 2020. UCB0107 is currently being investigated as a potential treatment for patients with tauopathies, initially focusing on progressive supranuclear palsy.

    In October, Keppra® (levetiracetam) was approved, in the U.S., for monotherapy in partial onset seizures. The new indication is intended for the use of Keppra® as mono-therapy in treatment of partial-onset seizures in patients one month of age and older and with an updated labeling to comply with the Pregnancy and Lactation Labeling Rule. An important driver for this submission was adding patient value, especially for pregnant women or women of childbearing age.

    In December, UCB launched Nayzilam® (midazolam) Nasal Spray CIV, the first and only nasal rescue treatment for seizure clusters in the U.S. Nayzilam® nasal spray was approved in the U.S. in May 2019.

    Immunology
    In July, Cimzia® (certolizumab pegol) was approved in combination with methotrexate for the treatment of moderate to severe, active rheumatoid arthritis in adult patients in China.
    In December, Cimzia® was approved for the treatment of psoriasis and psoriatic arthritis in Japan.

    During the course of the fourth quarter 2019, UCB reported positive results for three Phase 3 studies with bimekizumab in psoriasis:

    • In October, the study BE VIVID, evaluating the efficacy and safety of bimekizumab in adults with moderate-to-severe chronic plaque psoriasis met all primary and ranked secondary endpoints, including significantly greater efficacy compared to ustekinumab.
    • In November, the study BE READY, evaluating the efficacy and safety of bimekizumab versus placebo in adults with moderate-to-severe chronic plaque psoriasis, met all primary and ranked secondary endpoints.
    • In December, the study BE SURE, comparing bimekizumab to adalimumab for the treatment of adults with moderate-to-severe plaque psoriasis, met all co-primary and ranked secondary endpoints, achieving significantly greater efficacy than adalimumab.

    UCB plans to submit applications to regulatory authorities for approval of bimekizumab to treat adults with moderate-to-severe plaque psoriasis in mid-2020.

    In addition, based on a positive proof-of-concept study, UCB decided to move into late stage development with bimekizumab in moderate to severe hidradenitis suppurativa (HS), a severe inflammatory skin disease, affecting predominantly women. The Phase 3 program BE HEARD starts in Q1 2020. First headline results are expected in H1 2023.

    Evenity® (romosozumab) is now approved in Japan, the U.S., South Korea, Canada and Australia as well as in the EU.

    In October, following re-examination procedure, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), has adopted a positive opinion recommending Marketing Authorization.

    Evenity® was approved by the EMA in December for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture.

    Net sales break-down by core product(4)

    Immunology

    Cimzia® (certolizumab pegol) for patients living with autoimmune and inflammatory TNF mediated diseases, net sales increased to more than € 1.7 billion, driven by continued, sustainable growth in all regions. Growth is also driven by new patient populations like women of childbearing age and people living with non-radio-graphic axial spondyloarthritis and with psoriasis

    Neurology: UCB’s epilepsy franchise reached net sales of € 2.3 billion, a plus of 12%.

    Vimpat® (lacosamide), with net sales of more than € 1.3 billion, shows continued double-digit strong growth in all regions thanks to reaching more and more people living with epilepsy.

    Keppra® (levetiracetam) for epilepsy, reported net sales of € 770 million, reflecting both, the strong, trusted brand and the maturity of the product. In the U.S. net sales were impacted by generic competition. In Europe, Keppra® net sales were affected by a local, one-time rebate adjustment in the first half 2019

    Briviact® (brivaracetam), reached net sales of € 221 million. This is driven by significant, continuous growth in all regions where Briviact® is now available to patients

    Neupro® (rotigotine), the patch for Parkinson’s disease, showed a slight decrease of net sales to € 319 million. Smaller declines in the U.S. -due to the generic market environment – and Europe were almost compensated by good growth in international markets.

    2019 FY financial highlights(5)

    In 2019, revenue and net sales increased by 6% (+7% CER) to € 4 913 million and to € 4 680 million (+6%; +7% CER) respectively. Net sales before “designated hedging reclassified to net sales” went up by 11% (+7% CER) to €4 784 million. Adjusted for divestitures in 2018, mainly “Innere Medizin”/Germany and the iron supplement Niferex® in Q1 2019, and before ‘designated hedges reclassified to net sales’ growth was +13% (+9% CER). This growth was driven by the continued strong positive performance of UCB’s core products.
    Royalty income and fees decreased to € 78 million from € 92 million. Other revenue increased to € 155 million after € 128 million.

    Gross profit reached € 3 645 million, with a plus of 6% in-line with the net sales growths and reflecting a stable gross margin compared to 2018.

    Operating expenses reached € 2 527 million (+9%; +6% CER) reflecting 15% higher marketing and selling expenses of € 1 108 million – driven by the launch of Cimzia® in psoriasis in the U.S. and Europe and in active non-radiographic axial spondyloarthritis (nr-axSpA) in the U.S. as well as launch preparations for Evenity® in Europe, 10% higher research and development expenses of € 1 272 million – driven by higher R&D investments and resulting in a R&D ratio of 26% in 2019 after 25% in 2018 and 8% higher general and administrative expenses of € 195 million, mainly in connection with the new organization model implemented in 2019. Other operating income was € 48 million after expenses of € 24 million in 2018. The income is composed of investment grants, gain on divestiture, release of provisions and income from the collaboration with Amgen in connection with Evenity®. This resulted in an operating expense ratio (in relation to revenue) of 51% after 50% in 2018.

    Underlying operational profitability – rEBITDA(6) – reached € 1 431 million a plus of 2% (+11% CER) with higher net sales overcompensating increased expenses for product launches and product development. The rEBITDA ratio for 2019 (in % of revenue) reached 29.1%, from 30.2% in 2018.

    Total impairment, restructuring and other income/expenses (formerly called “non-recurring”) were expenses of € 50 million after an income of € 4 million in 2018. In 2019, this includes mainly restructuring expenses, but also legal and litigation costs, partially offset with income resulting from gain on the divestitures. In 2019, UCB strengthened its operating model to ensure maximum agility to meet the growth expectations for the years ahead, hence the restructuring expenses.

    Net financial expenses increased by 15% to € 107 million.

    Income tax expenses were € 146 million compared to € 200 million in 2018. The effective tax rate of 15% is driven by the higher group revenue and the increasing impact of R&D related tax deductions in key countries.

    Profit amounted to € 817 million (after € 823 million), of which € 792 million (after € 800 million) is attributable to UCB shareholders and € 25 million (after € 23 million) to non-controlling interests.

    Core earnings per share, which reflect profit attributable to UCB shareholders, adjusted for the after-tax impact of impairment, restructuring, other operating income/expenses, the financial one-offs, the after-tax contribution from discontinued operations and the net amortization of intangibles linked to sales, reached € 5.20 after € 4.78 based on 187 million weighted average shares outstanding.

    Dividend – The Board of Directors of UCB proposes a dividend of €1.24 per share (gross), +2%.

    Outlook 2020 – For 2020, UCB is aiming for revenues in the range of € 5.05 – 5.15 billion – thanks to the current core product growth and new patient populations being served. UCB will continue to advance its strong development pipeline to offer potential new solutions for patients and complement with external opportunities. Hence, the underlying profitability, rEBITDA6, in the range of 28-29% of revenue will reflect the high R&D investment level. Core earnings per share are therefore expected in the range of € 4.80 – 5.20 based on an average of 187 million shares outstanding. The figures for the outlook 2020 as mentioned are calculated on the same basis as the actual figures for 2019. The 2020 outlook will be updated upon closing of the planned Ra Pharma acquisition.

    New Composition of UCB’s Executive Committee in 2020

    Six consecutive years of growth have underscored UCB’s robust performance over time. UCB is poised to further accelerate and expand to deliver on its Patient Value ambition, potentially launching six or seven new products by 2025.

    “To support our ambition, we evolved our organization and ways of working to ensure we become more agile and collaborate more transversally across our organization. We believe this evolved organization will increase our operational clarity and efficiency, and will set us up for truly patient-value focused launches,” said Jean-Christophe Tellier, CEO of UCB

    This evolution is reflected in the new composition of the UCB Executive Committee which became smaller, with more transversal roles across businesses and regions, and with more focus on the company’s core activity areas.

    Since 1 February 2020 the new composition of the Executive Committee of UCB is as follows:

    • Jean-Christophe Tellier, Chief Executive Officer
    • Emmanuel Caeymaex, Executive Vice President Immunology Solutions & Head of US
    • Jean-Luc Fleurial, Executive Vice President & Chief Human Resources Officer
    • Iris Löw-Friedrich, Executive Vice President & Chief Medical Officer
    • Kirsten Lund-Jurgensen, Executive Vice President, Supply & Technology Solutions
    • Dhaval Patel, Executive Vice President & Chief Scientific Officer
    • Bill Silbey, Executive Vice-President & General Counsel
    • Detlef Thielgen, Executive Vice President, Chief Financial Officer & Corporate Development
    • Charl van Zyl, Executive Vice President Neurology Solutions & Head of EU/International

    Alexander Moscho, Pascale Richetta, Bharat Tewarie and Jeff Wren have left the Executive Committee and UCB is very thankful for their past contributions. Bill Silbey and Kirsten Lund-Jurgensen joined the Executive Committee in 2019.
    Furthermore, UCB announced in July 2019 that the company’s Chief Financial Officer, Detlef Thielgen, will be transitioning out of UCB in H1 2020. A search for a successor is ongoing.

    Further information about UCB’s Executive Committee are available on UCB website: https://www.ucb.com/investors/UCB-Governance#book-CMP_B_55790

    Find the FY financial reports on UCB website: http://www.ucb.com/investors/Download-center

    Today, UCB will host a conference call/video webcast at 08.00 (EST) / 13.00 (GMT) / 14.00 (CET).

    Details are available on https://www.ucb.com/investors/UCB-financials/Full-year-financial-results

    About UCB
    UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 600 people in approximately 40 countries, the company generated revenue of € 4.9 billion in 2019. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news

    Forward looking statements
    This press release contains forward-looking statements including, without limitation, statements containing the words “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to differ materially from those that may be expressed or implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring and retention of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB’ efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB’s products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB’s data and systems.

    Given these uncertainties, you should not place undue reliance on any of such forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labelling in any market, or at any particular time, nor can there be any guarantee that such products will be or will continue to be commercially successful in the future.

    UCB is providing this information, including forward-looking statements, only as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.

    Additionally, information contained in this document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction.

    (1) CER = constant exchange rates

    (2) rEBITDA = recurring Earnings Before Interest, Taxes, Depreciation and Amortization charges

    (3) Core EPS = core earnings per share

    (4) Due to rounding, some financial data may not add up in the tables.

    (5) Due to rounding, some financial data may not add up in the tables.

    (6) rEBITDA = recurring Earnings Before Interest, Taxes, Depreciation and Amortization charges

    Psorilax:Tecnica |pso crema dermaffine recensioni forum psoriasi

    0

    Psorilax: prezzo, funziona, recensioni, opinioni, composizione

    Semi di canapa sono essenziali nell'industria farmaceutica e farmaceutica poiché sono una delle migliori fonti di proteine ​​vegetali, acidi grassi essenziali e contenuto di fibre. Hanno la capacità di migliorare la salute del cuore, innescare la digestione, costruire massa muscolare, curare l'anemia, eliminare l'insonnia e sovvenzionare i problemi di perdita di peso. Quindi, prima di approfondire ulteriormente, diamo un'occhiata da vicino e proviamo a capire:

    10 migliori benefici nutrizionali dei semi di canapa

    La canapa, popolarmente conosciuta come canapa industriale, è una variante genetica della Cannabis Savita Plant. Sono coltivati ​​per la sua rafia fibra o i suoi semi commestibili, qui la fibra di rafia indica il materiale peloso di una pianta che è la corteccia interna di un albero. Quando si tratta di canapa, le persone si confondono sul loro contributo e lo confrontano con una pianta di cannabis che funge da fonte di Marijuana e hascisc. Indipendentemente dal fatto, tutti e tre i prodotti – Canapa, Marijuana e hascisc contiene composizione di tetraidrocannabinolo (THC).

    Pianta Di Marijuana

    La quantità di cannabis utilizzata per la formazione di Canapa contiene meno quantità di THC rispetto a quella utilizzata nella produzione di marijuana e hashish. Per capire meglio in che modo differiscono l'uno dall'altro, daremo un'occhiata a:

    Struttura chimica dei semi di canapa:

    Canapa è un'angiosperma che appartiene alla famiglia della cannabis e può essere facilmente coltivata in climi temperati, buone condizioni del suolo, fertilizzanti e acqua senza pesticidi ed erbicidi. Il raccolto viene raccolto per quasi 120 giorni (4 mesi) fino a raggiungere un'altezza di 10-15 piedi.

    Canapa i semi contengono approssimativamente il 30% di carboidrati, il 25% di proteine, il 15% di fibre insolubili, il carotene, il potassio, il fosforo, il magnesio, lo zolfo, il calcio, il ferro e lo zinco. È rinomata per essere una delle migliori fonti di acidi grassi essenziali con il perfetto equilibrio tra acidi grassi Omega-3 e Omega-6.

    La variazione di composizione di canapa il seme è diviso in diversi fattori, alcuni dei quali sono elencati di seguito in un formato tabulare:

    1.1 Analisi prossimale dei semi di canapa:

    SL.NO PARAMETRI SODDISFARE(%)
    1 Umidità 3.07
    2 Olio 32.21
    3 Proteina 23.9
    4 Cenere 4.32
    5 Fibra 17,3
    6 Carboidrato 28.5

    1.2 Proprietà fisiche dell'olio di semi di canapa:

    SL.NO PARAMETRI VALORE
    1 Stato fisico Liquido
    2 Colore Giallo grassetto
    3 Odore Piacevole nocciola
    4 Gusto blando
    5 Punto di congestione 15-72 ° C
    6 Indice di rifrazione (40 ° C) 1,46
    7 Peso specifico (20 ° C) 0.89

    1.3 Proprietà chimiche dell'olio di semi di canapa:

    SL.NO PARAMETRI VALORE
    1 Valore acido (mg KOH / g di olio) 2.15
    2 Valore di iodio (g / 100 g di olio) 163,5
    3 Numero di saponificazione (mg KOH / g di olio) 190.2
    4 Materia insaponificabile (% di petrolio) 0.26
    5 Numero di perossido (Meg / Kg) 7.2

    Quindi, dai dati di cui sopra, puoi vedere come Semi di canapa agire come una fonte di fattori nutritivi essenziali rispetto ad altri membri della famiglia della cannabis.

    Importanza dei semi di canapa come medicinali:

    Secondo la storia, varie parti della pianta di cannabis sono state elaborate per la formazione di Canapa, Marijuana, e hascisc che contengono componenti THC in quantità specifiche. Il THC è un composto che può creare un impatto pericoloso sul tuo corpo in quantità maggiori.

    Ma in Canapa semi, la quantità di THC è bassa rispetto ad altre forme di droga come Marijuana e hascisc ed è per questo Canapa i semi sono trattati come super-alimenti sani. Canapa i semi sono ricchi di acidi grassi Omega-3 e Omega-6 nel cui rapporto è noto per essere un anti-farmaco contro malattie cardiache, cancro, diabete e carenze autoimmuni.

    Questi colori verde brillante Canapa i semi contengono circa il 90% di acidi grassi polinsaturi. Con questo abbiamo sviluppato una buona comprensione del perché Canapa i semi sono considerati la migliore fonte di acido grasso, quindi ora esaminiamo i loro benefici:

    I 10 principali benefici nutrizionali dei semi di canapa ?:

    Parlando dei benefici, Canapa i semi sono stati usati per più di migliaia di anni nell'industria medicinale. Sono utilizzati in varie medicine tradizionali e integratori alimentari a causa dei loro effetti positivi e sono molto vitali nel trattamento di diverse condizioni di salute. Diamo un'occhiata ai benefici per la salute di Canapa semi in modo più dettagliato di seguito:

    1. Ricco di contenuto proteico:

    La ragione per cui Canapa i semi sono utilizzati nelle industrie medicinali a causa del suo ricco contenuto proteico. Contiene tante proteine ​​quanto i semi di soia (che è anche una buona fonte di proteine) i, e. In ogni 30 grammi di semi o 3 cucchiai di Canapa i semi possono contenere contenuto proteico di 9.46 grammi.

    Fitness-

    Sono considerate la migliore fonte di proteine ​​contenente tutti e nove gli aminoacidi essenziali. Un corpo umano non può formare tutti i nove amminoacidi essenziali che sono i mattoni delle proteine, quindi questa è la ragione Canapa i semi vengono assorbiti attraverso la dieta per ottenere un contenuto proteico sufficiente. L'arginina presente in Canapa i semi grazie alla presenza di aminoacidi migliorano la salute del cuore.

    2. Migliora la salute del cuore:

    Salute del cuore

    I semi di canapa hanno un impatto maggiore quando si tratta di salute del cuore in quanto possiede una vasta gamma di opzioni di cura tra cui un corretto equilibrio del livello di colesterolo o acidi grassi nel corpo. Canapa i semi contengono il rapporto corretto di acidi grassi Omega-3 e Omega-6 che è di circa 3: 1.

    Come suggerisce la ricerca, Canapa i semi sono unici nel loro genere e contengono già l'equilibrio perfetto. Per il normale funzionamento del corpo, il livello di grassi saturi nel corpo è molto essenziale in quanto

    • Previene l'aterosclerosi
    • Riduce gli infarti e gli ictus
    • E molti altri problemi legati al cuore.

    Canapa i semi hanno un alto contenuto di fibre che aiuta a eliminare il colesterolo in eccesso dalle pareti delle arterie.

    3. Potenzia il sistema digestivo:

    Digestive Health

    Secondo un diario di ingegneria, un rapporto afferma che Canapa i semi sono una meravigliosa fonte di fibre alimentari solubili e insolubili. Il ruolo principale delle fibre insolubili è quello di ammassare le feci e facilitare il passaggio attraverso il percorso digestivo, riducendo quindi i sintomi di diarrea e costipazione.

    D'altro canto, le fibre solubili sono soggette a rallentamento del processo di assorbimento del glucosio e aumento dei succhi digestivi e gastrici. La combinazione di questo tipo di fibre nel tuo corpo può aiutarti a evitare problemi di salute da lievi a gravi.

    4. Aiuta a alleviare l'insonnia:

    Insonnia-Disturbo del sonno

    Uno dei ruoli più importanti e vitali che Canapa il seme gioca in presenza di un alto contenuto di minerali con l'inclusione del magnesio che tende a creare una sensazione rilassante e rilassante in tutto il corpo.

    La presenza di magnesio nel corpo ha diversi benefici per la salute e ormoni che sono responsabili di indurre il sonno.

    Uno studio è stato recentemente pubblicato affermando che la serotonina viene prodotta quando il magnesio è amministrato nel corpo e viaggia fino al cervello che a sua volta viene convertito in melatonina (un potente aiuto per il sonno che ti dà una sensazione rilassante e rilassante). Questo è il motivo per cui Canapa i semi sono raccomandati per i pazienti con insonnia.

    5. L'olio di canapa può alleviare il disturbo della pelle:

    Trattamento del disturbo della pelle

    Gli studi suggeriscono che il perfetto equilibrio di acidi grassi Omega-3 e Omega-6 nel corpo aiuta il sistema immunitario a rimanere in forma a lungo termine. Olio di canapa e Semi di canapa sono una buona fonte di acidi grassi polinsaturi ed essenziali.

    Il rapporto tra Omega-3 e Omega-6 che ottieni Canapa i semi sono nel rapporto 3: 1 che è della gamma ottimale.

    applicando Olio di canapa alla tua pelle ti aiuterà a prevenire problemi legati alla pelle come:

    • Eczema
    • Acne
    • Psoriasi
    • Lichen Planus

    Sulla base di queste malattie sopra indicate, Canapa l'olio può agire come un'ottima fonte di integratori e può contribuire a una pelle più sana, più forte e catartica che è più resistente alle infezioni virali, batteriche e fungine.

    6. Tratta l'anemia:

    RBC

    Puoi trovare ferro dentro Canapa semi che è considerato come uno dei principali contenuti minerali che è parte integrante della formazione della costruzione dei globuli rossi nel corpo umano.

    Se il tuo corpo è carente nella formazione di ferro, allora è probabile che potresti soffrire di anemia.

    Qui è dove l'assorbimento di Canapa i semi entrano in gioco in quanto contengono la giusta quantità di contenuto di ferro per impedire al corpo di soffrire di anemia.

    7. Aumenta la massa muscolare e la crescita muscolare:

    Massa muscolare

    Sei un bodybuilder o una persona che sta cercando di guadagnare una buona quantità di fibre muscolari? Canapa seme proteine ​​in polvere è ciò di cui hai bisogno per guadagnare massa muscolare.

    Sì, hai sentito bene Canapa i semi contengono tutti e nove gli aminoacidi essenziali che sono considerati i mattoni delle proteine ​​del tuo corpo e proteina è l'elemento chiave necessario per la crescita e la riparazione dei muscoli.

    Ecco i nove amminoacidi essenziali di cui stavamo parlando:

    • istidina
    • isoleucina
    • leucina
    • lisina
    • metionina
    • fenilalanina
    • treonina
    • Triptofano
    • valina

    8. L'olio di canapa allevia l'artrite:

    Dolori articolari

    I ricercatori e molti altri portali di ingegneria lo affermano Canapa l'olio può svolgere un ruolo vitale nel trattamento di qualcuno che soffre di artrite. Quasi il 15% degli americani soffre di questo dolore cronico.

    I tipi più comuni di artrite sono:

    • Artrite reumatoide (RA): – Questo è un tipo di malattia autoimmune causata nel sistema immunitario di una persona che tende ad attaccare le articolazioni formando infiammazione. Questo tipo di artrite colpisce generalmente le mani e i piedi di una persona e porta a articolazioni dolorose, rigide e gonfie.
    • Artrosi (OA): – Questo è un tipo di artrite che colpisce la cartilagine articolare e le ossa causando dolore e rigidità. Questi sono problemi comuni che possono insorgere nel corpo umano che colpiscono le articolazioni dell'anca, del ginocchio e del pollice.

    Canapa l'olio è qualcosa che tende a svolgere un ruolo vitale nel sistema immunitario di un corpo umano gestendo il dolore e l'infiammazione. Lo scienziato crede, usando Canapa l'olio potrebbe svolgere un ruolo importante nella gestione del dolore cronico.

    9. Cura capelli, pelle e unghie:

    Trattamento per capelli

    Dai semi di canapa, possiamo ottenere Canapa olio che viene ampiamente utilizzato nei prodotti cosmetici e per la cura della pelle a causa dei suoi effetti rassicuranti su varie condizioni della pelle come dermatite, eczema, psoriasi, infiammazione della pelle e molti altri.

    Ecco alcuni degli effetti che Canapa i semi cercano di migliorare:

    • Ipertensione: La presenza di nove aminoacidi essenziali nell'olio di canapa tende alla formazione di induzione proteica chiamata idrosilato che abbasserà la pressione sanguigna prevenendo così il rischio di ictus e malattie cardiache.
    • Riduce la ricorrenza di alcol e droghe: L'olio di canapa è anche noto come olio di cannabidiolo che è un componente non psicoattivo della pianta di cannabis Savita può anche essere usato come scudo per combattere l'alcolismo e contenere le voglie di cocaina.
    • Regola gli ormoni: canapa: I semi contengono acido gamma-linoleico che funge da regolatore ormonale per coloro che soffrono di tiroide e pancreas. Aiuta anche a regolare lo squilibrio ormonale.

    10. Riduce lo stress e l'ansia:

    Stress e depressione

    Ansia, stress e sbalzi d'umore sono sintomi comuni con cui l'uno o l'altro è interessato. Olio di semi di canapa può un prezioso anti-dose per i pazienti chiropratici e tende a curare i disturbi dell'umore.

    Se stai seguendo una dieta ricca di proteine, ti aiuterà a superare il disturbo e olio di semi di canapa contiene tutti i minerali e le proteine ​​vitali necessari per alleviare lo stress e l'ansia.

    Questi sono alcuni dei punti vitali e più importanti sopra elencati per darti una conoscenza approfondita dei suoi benefici.

    Ora, non possiamo semplicemente parlare di tutti i benefici piuttosto che dichiarare alcuni degli effetti collaterali che potrebbe causare, quindi qui potrai presentare alcuni dei pochi effetti collaterali, che Semi di canapa potrebbe causarti:

    Effetti collaterali:

    Ci sono effetti collaterali minimi associati ai semi di canapa, se si soffre di una sorta di interazione farmacologica, è probabile che possa aumentare il rischio di sanguinamento se assunto insieme agli anticoagulanti.

    Un'altra cosa che dovresti tenere a mente, se sei incinta o porti un bambino, si consiglia di consultare il medico che ti guiderà con i farmaci adeguati durante questa fase.

    Ora abbiamo finito con tutti i possibili risultati che un seme di canapa può fornirci e siamo vicini all'ultimo possibile stadio del nostro conclusione, Scopriamolo:

    Perché dovresti prendere in considerazione l'uso di prodotti a base di semi di canapa?

    Come sei consapevole del fatto, quello Semi di canapa sono una potente fonte di proteine ​​con tutti e nove gli aminoacidi essenziali che contengono il rapporto perfetto tra acidi grassi Omega-3 e Omega-6 di un rapporto 3: 1.

    Questi semi di canapa sono considerati la pianta più nutriente del mondo e una fonte vitale di proteine ​​per vegani e crudisti. I semi di canapa sono utilizzati anche in numerosi prodotti alimentari e integratori, tra cui Latte di canapa, Proteine ​​in polvere, burro, prodotti insaturi e molti altri.

    Non solo prodotti alimentari, ma utilizzando Olio di canapa ti tiene lontano da problemi legati alla pelle per citarne alcuni:

    • Eczema
    • Acne
    • Psoriasi
    • Lichen Planus

    Ti aiutano a prevenire Artrite reumatoide, artrosi, e molti altri dolori associati alle articolazioni.

    Questi Piante di canapa sono considerate le piante più intraprendenti e sostenibili del pianeta con tutte le sue caratteristiche positive e nutrizionali.

    Con i suoi numerosi benefici, Semi di canapa stanno alimentando l'ambiente globale con i suoi aiuti nutrizionali.

    Psorilax:Recensioni |crema piedi per psoriasi

    0

    Psorilax: prezzo, funziona, recensioni, opinioni, originale

    Logo of jester cap with thought bubble.

    Image source: The Motley Fool.

    Bausch Health Companies Inc. (NYSE:BHC)
    Q4 2019 Earnings Call
    Feb 19, 2020, 8:00 a.m. ET

    Contents:

    • Prepared Remarks
    • Questions and Answers
    • Call Participants

    Prepared Remarks:

    Operator

    Good day and welcome to the Bausch Health Fourth Quarter and Full-Year 2019 Financial Results Conference Call. All participants will be in a listen-only mode. (Operator Instructions) After today’s presentation, there will be an opportunity to ask questions. (Operator Instructions) Please note this event is being recorded.

    I would now like to turn the conference over to Arthur Shannon, Senior Vice President of Investor Relations and Global Communications. Please go ahead.

    Arthur J. ShannonSenior Vice President and Head of Investor Relations and Communications

    Thank you, Alicia. Good morning, everyone, and welcome to our fourth quarter and full-year 2019 financial results conference call. Participating on today’s call are Chairman and Chief Executive Officer Mr. Joe Papa and Chief Financial Officer Mr. Paul Herendeen. In addition to this live webcast, a copy of today’s slide presentation and a replay of this conference call will be available on our website under the Investor Relations section.

    Before we begin, we’d like to remind you that our presentation today contains forward-looking information. We would ask that you take a moment to read the forward-looking statement legend at the beginning of our presentation as it contains important information. This presentation contains non-GAAP financial measures. For more information about these measures, please refer to Slide 2 of the presentation. Non-GAAP reconciliations can be found in the appendix to the presentation posted on our website. Finally, the financial guidance in this presentation is effective as of today only. It is our policy to generally not update guidance until the following quarter and not to update or affirm guidance other than through broadly disseminated public disclosure.

    With that, it’s my pleasure to turn the call over to Joe Papa.

    Joseph C. PapaChairman of the Board and Chief Executive Officer

    Thank you, Art, and thanks everyone on the phone for joining us today. Let’s quickly review the topics we will cover today. I’ll begin with a brief summary of our 2019 Company highlights before turning the call over to Paul Herendeen, our CFO. Paul will take us through the fourth quarter and full-year financial results and provide our 2020 guidance. I’ll then review the segment highlights and catalysts before opening the line for questions.

    Beginning on Slide 4, in 2019, our theme was pivot to offense or focus on driving organic growth in our core businesses. We have now delivered eight consecutive quarters of organic growth and 2019 was our first full year of reported revenue growth since 2015. Bausch Health grew organically by 4% in 2019 and reported revenues were up 3%. Our largest segment, B&L International delivered its third consecutive year of mid-single-digit organic revenue growth. Salix reported full-year revenue of more than $2 billion for the first time ever. We generated $1.5 billion of cash from operations. We increased R&D investment by 14% compared to 2018 and we used approximately $1.1 billion of cash to pay down roughly $900 million of debt and fund approximately $250 million of bolt-on acquisitions or licensing products. Pivoting to offense also include launching new products and driving their growth and our new products continue to grow.

    First, following the launch of Thermage FLX in Asia Pacific, the Thermage franchise saw 73% organic revenue growth compared to 2018. This exceptional growth rate made the Thermage one of the Bausch Health’s Top 10 franchises in 2019. Lumify achieved a weekly market share of approximately 43% in 2019, is the Number 1 physician-recommended product in the redness reliever category. Trulance TRxs grew by 31% year-over-year and we have improved the market access position for approximately 35 million lives since we acquired the product in the first quarter of 2019. Duobrii has been another standout. Weekly TRxs grew by 25% from the third quarter to the fourth quarter of 2019 and we have now achieved 63% commercial access. Overall, the entire Bausch Health team of 22,000 employees delivered on our promise to pivot to offense in 2019 and demonstrated the durability of our business, which we grew both organically and through strategic bolt-on acquisitions. Great effort by the entire Bausch Health team.

    Paul’s going to walk you through the fourth quarter and full-year results in more detail. So with that, I’ll turn it over to Paul.

    Paul S. HerendeenExecutive Vice President and Chief Financial Officer

    Thanks, Joe. A lot to cover. I’ll try to go fast. Good quarter and a good year, a little different approach this quarter. I’m going to start with Slide 5, a summary of the changes in revenue by segment and major business units for both Q4 and the full-year 2019. I’ll then walk down the top level P&L for the quarter and provide some observations about the full year before turning to our guidance for 2020. Quick reminder, when we talk about organic growth, that means excluding the impact of changes in FX rates, the impact of divested and discontinued businesses in the prior-year periods and the impact of acquired businesses.

    Okay, Slide 5. In the quarter, we posted 4% organic revenue growth versus Q4 of 2018. Recall that last year we took steps to reduce our channel inventories held at wholesalers and that that had the effect of reducing Q4 ’18 revenue by an estimated $76 million. So, that’s a tailwind for us this quarter. Excluding the impact of the inventory contraction, we still posted top level organic revenue growth of plus 1%. There were a lot of moving parts, but a lot of good stuff within each of our segments.

    Let’s start with Salix as it was the largest contributor of organic revenue growth in the quarter, up 17% organically on continued strong performance from Xifaxan, up 29%. Relistor up 29% and Plenvu also contributed growth. We lost exclusivity for Apriso in the quarter and that combined with the continued generic erosion of Uceris offset some of the growth. While not a factor in organic growth, Trulance sales totaled $18 million in the quarter and Salix TRxs were up 69% versus Q4 of ’18. A strong quarter from Salix to wrap up a great year, posting 13% organic revenue growth for the full year versus 2018, despite LOEs.

    B&L International segment revenue was up 3% organically in the quarter led by Global Consumer plus 7% organically on strength in Lumify in the US and our global contact lens solution brands Renu and Biotrue Multi-Purpose. Global Surgical was plus 5% organically in the quarter on strength in consumables for the back of the eye and enVista IOLs. Global Vision Care was plus 4% organically in the quarter on strength in ULTRA monthly silicone hydrogel lenses, our AQUALOX Daily SiHy lenses in Japan and Biotrue ONEday lenses. Our international pharma business was essentially flat versus Q4 of ’18 while Global Ophtho Rx declined 2% organically as growth of Vyzulta and Prolensa were more than offset by the decline of the Lotemax brand family due to generic erosion.

    For the full year, B&L International grew 5% organically, consistent with our belief that this diverse and durable segment can deliver mid-single-digit growth over time. All five of the B&L International business units posted organic revenue growth for the year, led by Global Consumer up 6% organically on strength of Lumify in the US and our eye vitamins globally, followed by Global Vision Care up 7% organically, with contributions from our Biotrue ONEday lenses, our monthly ULTRA lenses and our AQUALOX Daily SiHy lenses in Japan.

    Our international pharma business was up 5% organically on strength in Russia, Egypt and Canada. Global Ophtho Rx was up 2% organically. Unlike in the quarter, for the full year, growth of Vyzulta, Prolensa and a portfolio of our international ophthalmic brands overcame the LOE drag from Lotemax. The Ortho Dermatologics segment declined 1% organically in Q4 of ’19 versus ’18 as spectacular growth in our global aesthetics business Solta, which was up 42%, nearly overcame the 18% decline in medical dermatology. In the Solta business, the Thermage platform is now solidly in the Top 10 products for the entire company and was a significant contributor to companywide growth. LOEs played a big role in the quarterly decline in medical derm, mainly Elidel and Zovirax cream. The balance of promoted products in medical derm including Duobrii, Jublia, Siliq and Bryhali, all grew versus Q4 of 2018. It’s pretty much the same story for the Ortho Derm segment for the full year, strong growth from Global Solta plus 45% organically for the year, more than offset by the decline in medical dermatology. For the full year, medical derm was our business most impacted by LOEs, a minus $121 million growth drag versus 2018.

    On the plus side, Jublia was one of the Top 15 contributors to companywide revenue growth in 2019 versus ’18. As the impact of LOEs moderate in this segment, Jublia, together with our brands in growth phase, that’s Duobrii, Siliq and Bryhal, form the core of our medical derm portfolio and the basis for an expected return to growth in this business in 2020.

    Finally, the Diversified segment, which declined 5% organically in the quarter as LOEs were a $29 million (Phonetic) drag on the neuro business. Our generics business grew 3% organically in the quarter with authorized generic versions of our branded products that lost exclusivity, mainly Uceris, Apriso, Lotemax and Elidel providing the bulk of that growth. For the full year, Diversified declined 5% organically as a 11% growth of our generics business offset some of the $116 million LOE growth drag in our neuro business.

    Total company revenue for the year grew 4% organically, with 2% coming from improved realized net selling prices and 2% from increased volume.

    Flip to Slide 6, the P&L summary for the quarter. Our gross margin in the quarter was 71.4%, down about 20 basis points versus Q4 of 2018, mainly due to higher inventory write-offs in Q4 ’19 relative to the prior-year quarter. Note that for the full year, our gross margin was 72.7%, favorable by 80 basis points versus 2018 with mix a big driver, particularly impacted the growth of Xifaxan, but also from improvements associated with our Project CORE activities. Our final guidance for the full year for gross margin was roughly 73%.

    Selling and advertising expenses in the quarter were up — are unfavorable on a constant-currency basis by 6% versus Q4 of 2018 due to the addition of Trulance to the Salix portfolio and higher A&P costs in Vision Care to support new launches and in international pharma for product launches, particularly in Canada and Russia. Adjusted G&A expenses on a constant-currency basis were 8% unfavorable in the quarter compared to Q4 of 2018 due to increased cost of business development initiatives and higher ongoing IT costs as we continue to work to improve our global operating systems. I want to point out that in Q4 of 2019, adjusted G&A run rate, is above what I would expect on average the quarterly run rate to be in 2020. The go-forward adjusted G&A run rate is likely between the $163 million we saw in Q4 and the $140 million average over the first three quarters of 2019. R&D was down in the quarter or favorable by 5% on a constant-currency basis. I would not read much into that. It’s just how the timing of expenses fell in both periods. For the full year, R&D was up 15% on a constant-currency basis to $471 million, slightly below our final 2019 guidance for R&D of $480 million. Again, just the timing of how expenses fell. As you’ll see when I get to 2020 guidance, we intend to commit more capital to R&D activities.

    Adjusted EBITDA in the quarter was $898 million, up 5% from the year-ago quarter on a constant-currency basis, a solid quarter that enabled us to post adjusted EBITDA of $3.571 billion for the full year, which was plus 4% on a constant-currency basis from 2018 and just below the top end of our final guidance range for 2019.

    Turning to Slide 7. I think it’s worth taking a look back at how we did in 2019 relative to the midpoint of our original 2019 guidance, which was $8.4 billion of revenue and $3.425 billion of adjusted EBITDA. Our actual 2019 revenue was $201 million above the midpoint of original guidance with a favorable result a function of four things. The acquisition of Trulance added $55 million, revenue from LOE assets was plus $53 million, our base business was favorable by $115 million, and offsetting the good guys, changes in FX rates reduced revenue by some $22 million. Adjusted EBITDA was $146 million above the midpoint of our original guidance. FX had no impact, Trulance had no impact, the better LOE revenue has added $36 million of profit, the better base performance added $71 million of profit, while investment in R&D and SG&A spending were both a bit above our original view. The biggest single factor in the improved adjusted EBITDA was our gross margin coming in at 120 basis points better than initially forecast, which accounted for roughly $100 million of lift. Point of the story is that, as the year played out, we had some good fortune with the LOE assets, but the lion’s share of the better results came from our commercial units driving improved performance in our base businesses, from our Project CORE activities to improve gross to nets, and from our relentless efforts to improve efficiency in our supply chain, a good year.

    Turn to Slide 8, the cash flow summary. Our net cash provided by operating activities in 2019 came in at $1.501 billion, the low end of our expected range as we increased inventories of certain key products and API to ensure uninterrupted supply. Note that at year end, we had $3.244 billion of cash on hand as we completed an offering of $2.5 billion of unsecured notes in late December and had not yet applied those proceeds to the payment of the US Securities Litigation, that’s $1.21 billion and the prepayment of other debt totaling $1.24 billion. Net of those amounts and related fees, our working cash at year end was roughly $750 million.

    Similarly on Slide 9, the cash and debt on our balance sheet at year end are inflated due to the timing of the $2.5 billion debt raise and the use of those net proceeds. I think of it like this. Pro forma for the deployment of those funds, our net debt at year end would have been roughly $24.2 billion. Settling the US Securities case, set us back in our progress reducing the quantum of our debt and improving our leverage ratios, but it was absolutely the right thing to do to quantify and settle a significant overhanging uncertainty. Quick aside, just last week, we began the process of calling another $100 million principal amount of bonds. We intend to continue to systematically grind our debt down. One last thing on the balance sheet. During the quarter, we accrued for the settlement of the US stock drop case, other related cases, and ongoing legacy litigation and investigations. The total accrual was for $1.39 billion and is included in GAAP other income and expenses in our P&L. For the avoidance of doubt, we exclude this expense from the computation of adjusted EBITDA and adjusted net income.

    Finally and onto the money slides for me, starting with Slide 10, showing our guidance for 2020. Our revenue guidance for 2020 is a range of $8.65 billion to $8.85 billion and that represents a range of growth of plus 1% to plus 3% at current FX rates. Our adjusted EBITDA guidance is a range of $3.5 billion to $3.65 billion, representing a range of growth of minus 2% to plus 2% at current FX rates. I want to cover the other elements of our guidance on this slide before talking about how to think about those revenue and profit growth rates for 2020.

    Adjusted SG&A expenses were $2.5 billion in 2019 and we’re guiding to approximately $2.6 billion for 2020. The roughly $100 million or 4% increase is higher than it may be as we look ahead to 2021 and 2022. In our 2020 plan, we rationalized opex across several business units, but we also allocated incremental selling, advertising and promotional resources to some units to support launch products and products in launch phases, including Daily SiHy lenses, Lumify, Duobrii, and Thermage.

    In G&A, we are continuing to build out our global IT organization and infrastructure and that comes at a cost, increasing our adjusted G&A in 2020 versus 2019. As we move forward into 2021 and 2022, we should be able to hold the growth of SG&A below that of revenue growth. We’re guiding to roughly $500 million in R&D for 2020, up roughly $30 million from 2019. If you go back to 2017, our investment in R&D totaled $361 million. Over the last few years, we’ve built up the R&D organization and infrastructure to support an increased volume of product to sustain each of our core businesses. That includes reducing the investment intensity in some areas, while increasing commitments to other areas where we had been underinvested over a number of years and that’s specifically GI, B&L Surgical and Optho Rx. While a 6% increase in R&D reduces our near-term earnings and earnings growth, it’s the right thing to do to enhance our prospects to deliver long-term organic growth.

    For interest expense, we’re guiding to $1.55 billion, down from $1.6 billion, despite the addition of $1.21 billion of debt to fund the settlement of the US Securities class action. Our tax rate on adjusted earnings was 7.8% in 2019. We expect that rate to be about the same, roughly 8% in 2020. Towards the bottom of the page, note that we’re guiding to capital expenditures in 2020 of roughly $300 million. In the past, I’ve said that our steady state capex might be roughly $160 million to $175 million per year and that the uptick in 2019 was mainly due to investments in connection with the daily silicone hydrogel lens initiative and our build-out of our global IT systems. Over time, we’ve determined that under investment, particularly in our supply chain over the last number of years, necessitate increased investment in 2020 and beyond. It’s our current view that after roughly $300 million of investment in 2020, we will likely see capex requirements decrease in 2021 and again in 2022 are steady state, a few years out, maybe closer to $225 million of capex per year.

    Contingent consideration milestones and license agreements totaled $58 million in 2019 and we’re guiding to roughly $100 million in 2020. The increase was related to a forecast sales milestone on Relistor and payments related to the recently acquired rights to Xipere and NOV03.

    Finally, restructuring and other. In 2019, these items totaled $52 million. In 2020, we’re guiding to $75 million. I’d point out that this item represents our estimate of restructuring costs, some systems integration and settlement of legal cases and investigations.

    Turning to Slide 11, the bridge from 2019 actual results to our 2020 guidance. First, focus on the LOE impact. We are forecasting a $275 million of growth drag from the basket of LOE assets in 2020. The good news here is that we are finally close to putting the impact of the large bucket of LOEs behind us. In 2007 (Phonetic) versus ’16, the growth drag was $486 million. In ’18 versus ’17, it was $289 million. In ’19 versus ’18, it was $360 million. Over the last three years, our revenue growth was trammeled by more than $1.1 billion of LOE drag. In 2020, we expect the drag to moderate to $275 million. And here is the good part. That’s based on us realizing revenues on the LOE basket of $237 million in 2020 and while that amount will decline into 2021 versus 2020, the drag will be substantially reduced. We did not add any new LOEs to the LOE basket in 2020. And looking out over the period from ’21 to ’23, we expect the impact of future LOE assets to be quite manageable.

    The base performance of plus a $100 million — excuse me, $415 million is impacted in negative ways by a few things that I called out on our last call and a few others worth noting. First, there is the non-recurrent portion of the improvements in gross to nets that we saw in 2019 and especially in Q3 that are a headwind to 2020 growth. Next, the trajectory of the — is the trajectory of Glumetza. Glumetza had been a strong performer through the first three quarters of 2019 before as we forewarned, it dropped almost in half in Q4 and is now expected to trend downward from there in future quarters. Next and one I had not previously called out for you, we had terrific performance in our generics business in 2019 with major contributions from the authorized generic versions of Uceris and Elidel. As more generic versions of these products have launched, we will see significant declines in revenue for our AGs in 2020. Think of the AGs as us stretching the tail of brands that lose exclusivity. It’s good, but it’s fleeting.

    One other bit of color. The base performance could have been better, but our guidance includes an estimate of a meaningful headwind on our Asia-Pac region, especially China, associated with the coronavirus situation. Our revenue guidance includes a roughly $50 million coronavirus impact. That’s an estimate and we’ll see how this plays out over 2020. Obviously this impacted our adjusted EBITDA guidance as well. So, these items are part of the reason why the revenue growth in 2020 implied by guidance is only in the range of 1% to 3% at current FX rates.

    Turning to the EBITDA bridge at the bottom of the page, the currency LOE in R&D impacts are self-explanatory. Within the base performance, we’re absorbing the roughly $100 million or 4% increase in SG&A and the coronavirus impact on our revenue expectations impacts our adjusted EBITDA as well. All these items together are drivers of the adjusted EBITDA growth rates implied by our guidance ranges being below that of our revenue growth rate.

    That’s it for me. Back to you, Joe.

    Joseph C. PapaChairman of the Board and Chief Executive Officer

    Thank you, Paul. On Slide 12, there is a lot of information, but the important message to highlight is we have now delivered three consecutive years of mid-single-digit organic revenue growth for B&L International. B&L International was up 6% in 2017, up 4% in 2018, and up 5% in 2019.

    Turning to Slide 13, Global Vision Care has been a strong performer and I want to highlight two products that have been key drivers of the growth in this business, Biotrue ONEday and ULTRA contact lenses. We’ve shown five-year reported revenue for each in the charts on the bottom of Slide 13. On the left, from 2015 to 2019, Biotrue ONEday lenses had a 22% compound annual growth rate and in organic revenue grew by 23% in 2019. On the right, our ULTRA lenses had a 32% CAGR over the past five years and grew organically by 24% in 2019. We’ve called out the significant milestones that drove incremental growth, including the launches of lenses for astigmatism, presbyopia, and extended wear. This strong performance underscores the durability of these products and the strength of the Bausch & Lomb brand. We are seeing increased market share in US Vision Care. This business gained 1.6 share points to 11% unit share for the month of December 2019 versus a 9.4% share in December 2018. Finally, we plan to launch our daily silicone hydrogel lenses in the US later this year. Silicone hydrogel lenses are one of the fastest growing segments of the content — of its market.

    Turning to Slide 14 for an update on Global Consumer, I want to highlight two franchises. First, our top-selling eye vitamin portfolio in the US Ocuvite and PreserVision grew organically by 4% in 2019 and had a CAGR of about 7% from 2015 to 2019. And second, Lumify, the Number 1 physician-recommended product in the redness reliever category had sales of $63 million in 2019 and achieved a weekly market share of approximately 43%.

    On Slide 15, we highlighted enVista’s performance in our Global Surgical business. The enVista family of intraocular lenses or IOLs are clear artificial lenses that eye surgeons use to replace a person’s natural lenses when it becomes too cloudy due to a cataract. enVista grew organically by 36% in 2019. The chart below provides enVista’s reported revenue for the past five years, which grew at a 22% CAGR. We also launched an enVista toric in 2019, which we’ve shown on the bottom right. Looking ahead to the 2020 catalysts, we expect to launch an extended depth of focus intraocular lens platform in 2020. With the introduction of this platform, we will be entering the premium IOL segment, outside the US. And finally, we expect to launch a pre-loaded IOL injector platform for enVista IOLs in the second quarter of 2020.

    Moving now to Slide 16, before we go through the key highlights for Salix, I want to address two updates. First, after reviewing our GI portfolio in light of market opportunities, we decided to increase promotional focus of Xifaxan and Trulance and have discontinued promoting Doptelet and Lucemyra. Also, we recently received notice that Norwich Pharmaceuticals have filed an ANDA for rifaximin 550-milligram tablets. Alfasigma and Bausch Health will file suit against Norwich, alleging patent infringement and will trigger a 30-month stay of approval. We remain confident in the strength of the 23 patents covering Xifaxan and we will continue to vigorously defend our intellectual property.

    The chart on the right shows Xifaxan TRx growth over the past nine quarters. As you can see, TRxs grew by 7% from 2017 (Phonetic) to 2018 and by 8% from 2018 to 2019. For IBS-D specifically, TRxs grew by 15% in 2019 compared to 2018. Moving now to Relistor, TRxs grew by 6% in 2019 and beginning in 2020, we recently improved Relistor’s Oral market access position for more than 50 million lives. Finally, Trulance. TRxs grew by greater than 30% in 2019 and since the acquisition, we have improved the market access position for approximately 35 million lives. We are seeing progress in the IBS-D branded market where Trulance new Rx market share grew by — from 3.9% to 6.4% in 2019.

    Onto Slide 17, Ortho Dermatologics. First, Duobrii TRxs were up 25% in the fourth quarter compared to the third quarter and we’re very pleased with this launch. As we show in the chart on the bottom left, within two quarters of launch, Duobrii is capturing approximately 40% of new patients who were started on a first-line branded topical or oral psoriasis product. When you look at Duobrii against these three competitors listed, we believe it gives a perspective on the opportunity for Duobrii and the potential savings that could result from delaying the need to start patients on a biologic. Also, I am delighted to say that Duobrii is now at 63% commercial access for the United States and we gain — as we gain incremental coverage, we expect to reduce couponing support and expect gross to nets will improve over time. Importantly, average selling price increased from the third quarter and we ended the year with a higher ASP. We are clearly moving in the right direction. We are very enthusiastic about the opportunity for Duobrii, primarily because for the first time, we can offer psoriasis patients a topical product with a high potency corticosteroid that they can treat to clearance, rather than being limited to a certain duration of time.

    Moving now to Siliq, TRxs grew by 100% in 2019 compared to the prior year and we achieved 67% (Phonetic) commercial access. Bryhali TRxs were up 60% in the second half of 2019 compared to the first half and Bryhali now has 71% commercial access. We believe access rates of 60% to 70% demonstrate that managed care recognizes the value and the efficacy of our psoriasis products in helping to improve patients’ lives. On the right, we highlight a new cash-pay model for our prescription dermatology products in United States that’s now available online at dermatology.com. Telemedicine and e-commerce are available on the platform as of yesterday. Iconic products such as Retin-A will be available on dermatology.com as well as new products like Altreno. The platform was launched with a portfolio of 15 products and we plan to expand the number of cash-pay products over time. We believe that dermatology.com has the potential to meet patient needs and help grow our dermatology business.

    Turning to Slide 18, our aesthetics business Global Solta grew organically by 42% in the fourth quarter of 2019 versus the fourth quarter of 2018 and 45% in the full year, driven by the global expansion of Thermage FLX. Thermage is a non-invasive radio frequency therapy that can address the signs of aging skin. You can see the trend in the chart on the left with a 46% CAGR from 2017. Looking ahead to 2020 and beyond, we expect to see continued global expansion for Thermage FLX, including geographic expansion in the EU.

    On Slide 19, you can see we have a good number of late-stage development programs in each of our core business segments. We increased R&D investment in 2019 versus 2018 and allocated a greater percentage of our R&D budget to Bausch & Lomb and Salix on a full-year basis. Launching new products will drive our future growth and we are pleased to have active late-stage pipeline of innovative new products with potential to expand our eye health GI in dermatology portfolio.

    I’ve talked about some of the programs along the way, but I want to highlight a couple of them in more detail. Before we turn to Slide 20, at the beginning of 2018, we identified the Significant Seven as key drivers of future growth and these seven products grew collectively by 68% in 2019. While we are pleased with that growth, limiting ourselves to seven products and excluding growth products like Biotrue, ULTRA, PreserVision, enVista IOL, Thermage, Aplenzin, Trulance and Xifaxan doesn’t give a complete picture of the expected drivers of our future revenue growth. Accordingly, we will continue to report revenue for our Top 10 products for each business and in overall for Bausch Health, but would no longer report combined revenue for the Significant Seven.

    Let’s turn to Slide 20 for additional detail on our promising late-stage programs in GI and eye health. Amiselimod is a late-stage oral compound that targets the S1P receptor, which plays an important role in autoimmune diseases such as inflammatory bowel disease. Approximately 1.6 million Americans currently suffer from IBD and as many as 70,000 new patients are diagnosed in US annually. We entered into an exclusive licensing agreement with Mitsubishi to develop and commercialize amiselimod in April 2019. In January ’20, we completed an FDA-approved cardiovascular clinical trial protocol that compared amiselimod to placebo and moxifloxacin. The primary endpoint demonstrated that amiselimod had no effect on QT interval prolongation and no other secondary safety signals were identified. We expect to initiate a multi-arm, randomized, placebo-controlled Phase 2 study in 2020 in ulcerative colitis for amiselimod.

    On Slide 21, we highlight NOV03 which we recently licensed in for the US and Canada. NOV03 is a non-aqueous eye drop for the treatment of dry eye. The prescription dry eye market represents a great opportunity with 6.8% of the US adult population projected to have diagnosed dry eye disease and prevalence will increase with age. If approved, NOV03 will be the first new prescription treatment for dry eye disease with mechanism of action that is different from currently available products. A Phase 2 study has already been completed which showed significant and clinically meaningful improvements in both signs and symptoms of dry eye disease. There is a Phase 3 study under way and we expect to initiate a second Phase 3 study later this year.

    To wrap up, on Slide 22, we have provided an overview of the 2020 vision for our three core businesses, which includes both a look back and what has driven performance and a look ahead to what is coming into focus for 2020.

    First Bausch & Lomb. We expect mid-single-digit growth to continue for 2020 based on five years of organic revenue growth for ULTRA, Biotrue and Ocuvite and PreserVision and new products like Lumify and Vyzulta. Looking ahead, we see significant opportunities into SiHy launch in the US and EU and the rest of the world, the ramp of our enVista IOL platform and the expected launch of an extended depth of focus for the IOL platform.

    Next in Salix, while absorbing the headwinds from Apriso and Glumetza in 2020, our GI business will be based on two years of high-single TRx growth for Xifaxan, increased market share for Trulance, and double-digit growth driven by market access for our Relistor Oral business. In 2020, we are planning to look forward to also the Plenvu ramp-up, continue to develop of new formulations and indications for rifaximin and pipeline expansion including dolcanatide and amiselimod.

    Third in Ortho Dermatologics, we expect this business to return to growth in 2020 based on a 73% organic revenue growth for the Thermage franchise, weekly Duobrii TRx growth and increased commercial access, driving improved gross to nets and the continued ramp of launch products including Siliq, Bryhali, and Altreno. Looking head, we see opportunity in building out the cash-pay model with more products, telemedicine and e-commerce and the launch of ARAZLO.

    Finally, we continue to expect to deliver on our three-year CAGRs on a constant-currency basis and from the midpoint of 2019 guidance, we expect revenue to grow at 4% to 6% CAGR and adjusted EBITDA to grow at 5% to 8% CAGR.

    With that, operator, let’s open up the line for questions.

    Questions and Answers:

    Operator

    (Operator Instructions) The first question today comes from Terence Flynn of Goldman Sachs. Please go ahead.

    Terence FlynnGoldman Sachs — Analyst

    Great. Thanks for taking the questions. Maybe two for me. Just wondering at a high level, what’s embedded in your 2020 guidance for net pricing across the portfolio, how that compares to 2019. And then on SiHy, the launch in Japan, I was wondering, any details you can share on market share and then how we should think about pricing, and positioning as you approach the US launch. Thank you.

    Joseph C. PapaChairman of the Board and Chief Executive Officer

    Okay. Let me start on our pricing — net pricing. Our expectation is that we’ll have somewhere in that 2% range approximately. That’s very consistent with what we saw in our 2019 information. Net pricing was approximately 2%. We expect it to be something comparable to that. Now, there will be some variation between product A and product B, but on balance there.

    In terms of the SiHy market share gains in Japan, we’re pleased with our initial launch in Japan. There were some issues that we had to deal with as we launched a new product, but on balance, we are pleased with what we’ve seen in terms of that launch and as Paul said in previous quarters are — importantly as we look at the Japan market, we believe the SiHy market as a percentage of Japan is about 15% and is growing by about 31%, so — the SiHy market that is. So, we think it’s an important contributor to growth and will be an important contributor for a long time and also as we launch here in the US later this year. The US is a little smaller percentage of total market in the US. It’s less than I think 13%, but we also see it growing quickly. So, we’re excited about what that means for us. We probably aren’t going to say anything about pricing yet on the SiHy Daily, but I think you could take it that we’ll be competitive with the other products out in the marketplace in the US SiHy Daily business.

    Next question, operator?

    Operator

    (Operator Instructions) The next question comes from David Amsellem of Piper Sandler. Please go ahead.

    David AmsellemPiper Sandler — Analyst

    Thanks. I wanted to focus on Xifaxan and looking at the IQVIA retail data in January, it looks like the growth trajectory of prescriptions is a little more muted compared to 2019. So, I’m wondering if there’s any indication that the franchise is maturing in any way and how should we think about the trajectory of volumes for both IBS and AG as we move more into 2020. Thanks.

    Joseph C. PapaChairman of the Board and Chief Executive Officer

    Sure. I’ll start with that one. We always see some normal variation in the early year, especially as patients have the donut hole questions and different reimbursement challenges as we start the year. So, we don’t see anything specifically happening there that is unusual relative to what we’ve seen in the past. I think as you think about trajectory, I mean, if you — one of the comments I made was talking about Xifaxan specifically relative to IBS-D. I remind you that within IBS-D, we were growing, I think, it was mid double digits, somewhere around 15%.

    And importantly, we believe the opportunity there is still very significant for us with Xifaxan. I remember that the IBS-D category, for example, has about 9 million — I’m sorry, has about 12 million antispasmodic prescriptions and as we’ve looked at that, we’re less than, let’s call it, 10% of that business. Therefore, we believe we’ve got a great product for IBS-D patients where with the episodic treatment, you can potentially get these patients to just move off of these products like the antispasmodics like Bentyl dicyclomine and actually get relief from — long-term relief from use of Xifaxan. And so, we’re going to continue to promote that area and we continue to expect to see that growth going on into the future to be clear.

    Operator, next question?

    Operator

    Your next question comes from Ken Cacciatore of Cowen & Company.

    Ken CacciatoreCowen & Company — Analyst

    Good morning and congratulations on all the progress. I know from time to time you’re asked about splitting or selling some of the businesses, but I was wondering as you get more credit for your performance in the underlying value of all the entity and everything that you’re doing, your equity is clearly responding. So, just wanted to know strategically how you view your equity. Is it something that you would think about using to deleverage. Is it something you’re thinking about in terms of maybe larger acquisitions? Just wanted to get your thoughts on that. Thank you.

    Paul S. HerendeenExecutive Vice President and Chief Financial Officer

    Yeah. Thanks for the question, Ken. It’s Paul. Yeah, our equity has responded. It kind of opens the door to potentially using that equity in some way. I’d say that for now, I mean, we have a great deal of runway to continue to run our businesses and using equity to reduce our leverage just based on a quantum of our debt and what it would take in order to make a meaningful change, probably not the path we go down.

    Now using equity in the context of a value-generative transaction, obviously, would have to be the right transaction and something we were incredibly excited about, but we would indeed consider that. I want to touch on, because it’s interesting. We haven’t heard the question as often about splitting the Company up over the last, I’d say, several months as the stock has performed better, but I think when you look longer term, the trend in — the overall trend in financial markets is for a preference on the part of investors for pure plays and we own a bunch of great businesses that are today together and I think that they are stronger — we are stronger with those businesses together today in light of our capital structure, but as we look down the road someday, down the road, there may be opportunities to pursue more pure plays with respect to one or more of our businesses, but that’s just something that’s down the road.

    Ken CacciatoreCowen & Company — Analyst

    Thank you.

    Joseph C. PapaChairman of the Board and Chief Executive Officer

    Operator, next question please.

    Operator

    The next question comes from Umer Raffat of Evercore.

    Umer RaffatEvercore — Analyst

    Hi (Technical Issues) my question. I have two if I may, one for you, Joe, maybe both for you Joe, OK. Joe, clearly characterized the pivot to be offense and the EBITDA growth of 5% to 8%, but in light of the guidance for this year and in light of our raging investor debate on whether the base business is truly a growth business in the first place, I’m curious, do you feel strongly that the 5% to 8% CAGR is achievable, especially, this year tracks at the midpoint of the guidance.

    And secondly, I was very curious about the S1P1 press release you guys put out in January, not only because I could still never find the trial online anywhere. So, I was curious where it was actually done and — but also, it seemed to me that the issue with the drug was cardiovascular adverse events and not exactly a QT signal. So, I was curious that FDA asked to do a QT study as a clearing event for larger trials? Thank you so much.

    Joseph C. PapaChairman of the Board and Chief Executive Officer

    Okay. So, I’ll start on the first part of the question of what we’re thinking — pivot to offense and guidance, but I am going to also turn it over to Paul who has worked his way through that. And then, I’ll comment on the S1P modulator. So the simple answer to your question on the CAGRs, are we confident, the answer is yes. We continue to look at that revenue guidance of 4% to 6% growth and then the 5% to 8% on the EBITDA as something that is achievable and I’m going to let Paul comment more about that specifically. But the simple answer is yes, and Paul, do you want to make some specific comments, and I’ll come back on the amiselimod.

    Paul S. HerendeenExecutive Vice President and Chief Financial Officer

    Yeah, sure. I mean and thanks for the question, because we — Umer, because we do get this question a fair amount. Joe said in his remarks. So that’s a refresh of what we meant when we said 4% to 6% and 5% to 8%, it was off the midpoint of our original 2019 guidance at constant currency. If you adjust that, you could come up with a range of targets for 2022 in order to meet that CAGR in the range of say $9 billion — circa $9.4 billion to $9.95 billion at revenue, $3.9 billion to $4.29 billion (Phonetic) for adjusted EBITDA. Yeah, we continue to believe that we can and will produce revenue and adjusted EBITDAs in that range.

    I mean, that’s our current belief. Obviously, not a forecast or a bit of guidance that we take lightly. It is fully supported by our bottoms up long-term view of what we think we can do with each of our businesses. I want to point out because people lose sight of this. As I said it was off the midpoint of 2019 guidance. I spent some time in my prepared remarks talking about how we did in 2019 relative to that original midpoint. We did better. So, that helps us along the road. I think people are going to look at our revenue forecast, revenue off of our guidance range of plus 1% to plus 3% and adjusted EBITDA of minus 2% to plus 2%, say, gee, you’re not on track to say — first of all, we’ve said this a million times. It’s not linear and we are focused on where we need to be in 2022 in order to be able to achieve those targets that we set for ourselves and we remain confident that we can achieve those targets. The good news is, we had a great 2019. The bad news is part of that was through LOEs that continued on. We’re delighted to have earned the profit and have generated the cash from those LOEs, but that goes away. And so, it has a bit of a growth track for us in 2020. Net-net, we are on track.

    Joseph C. PapaChairman of the Board and Chief Executive Officer

    On the second part of your question, Umer, on the S1P modulator amiselimod, the trial that we did was an FDA-approved protocol that we had gone and had the FDA approve the protocol. So, we had that in place. We wanted to solve that question or answer that question so that we were assured that there was no Q2 elongation issue. As you know, the cat products in this category have had that problem and we wanted to make sure that that was not going to happen with this product. We had a belief that it wasn’t, but we finished — we wanted to finish the definitive trial for amiselimod to get to that answer. So, that is the reason we did it. There was no request or anything. It was just, we had asked and had that as part of the information that we acquired when we received the product from Mitsubishi on amiselimod. So, I think that answers that part of the question. On the rest of it, we will publish this trial. It has not been published yet, but it will be published and presented in a poster session in the not too distant future. And I think that was the other part of the question.

    Okay. Operator, next question please.

    Operator

    The next question comes from Gregg Gilbert of SunTrust.

    Greg FraserSunTrust — Analyst

    Thank you. It’s Greg Fraser on for Gregg Gilbert. On Xifaxan, can you comment on payer coverage for the IBS indication and whether there is any room for improvement there? And can you also please comment on your initiatives to drive higher growth for the HE indication? Thank you.

    Joseph C. PapaChairman of the Board and Chief Executive Officer

    Sure. We have very strong coverage for Xifaxan. Overall, it’s 98.7%. HE is a little bit stronger, but at that level, it’s essentially universal coverage. I mean, we’ve got very strong coverage on Xifaxan. There is some variation from plan A to plan B, but we’re very pleased with that. On the question of HE, our view is that, we are going to continue to try to improve the compliance and adherence to the product. We have great data that says that if a patient stays compliant with Xifaxan, you can reduce rehospitalization for hepatic encephalopathy and if we’re able to do that, obviously we could save the healthcare system tremendous amount of dollars. So that’s our plan and our focus and we continue to go out and share that data with plan so that they can help lower the cost.

    Our fundamental belief though is that as healthcare plans and there’s mergers where the medical and the pharmaceutical comes together, we believe we’re going to have even more traction of that as we look at the opportunity to not only lower the total cost of the patient from the point of view of both the drug cost and the cost of rehospitalization, etc. So, that’s our plan and that’s how we’ve been working on it. We think it’s going to be important for patients going into the future with hepatic encephalopathy, and that — you may recall from our previous comments, we’re even looking at trying to get to some of these patients before the actual hepatic encephalopathy by going after some clinical trial evidence that we see in patients who have psoriasis. So, a lot more work. So, stay tuned to that for the future.

    Next question, operator.

    Operator

    The next question comes from Jason Gerberry of Bank of America.

    Jason GerberryBank of America — Analyst

    Good morning, thanks for taking my questions. So, quick question on Xifaxan. I think previously in September, you communicated around a 10% to 12% range of growth with minimal contribution from Project CORE. I just wanted to confirm if that’s still the fundamental outlook. And then just on the Significant Seven, is the change in disclosure more or less, hey, this is indicative of our broader pipeline value or is there a diminished outlook as it pertains to the $1 billion target end of 2022? Thanks.

    Joseph C. PapaChairman of the Board and Chief Executive Officer

    Paul, why don’t you take the first part of that?

    Paul S. HerendeenExecutive Vice President and Chief Financial Officer

    Yeah. Yeah, on the first part of that, I think, what we said was, we kind of continue to believe that Xifaxan would in 2020 versus 2019 that the way — the best way to forecast that would be to think about TRxs growth and use that as a proxy for unit growth and I think we continue to believe that that can be in the high single digits. And to that, you need to add a couple of hundred basis points of net price increase and the reason it’s only a couple hundred basis points is that non-recurring part of the revenue that we saw in 2019 related to the non-durable part of the improvements in gross to nets, some of it is reflected in absolutely improved net selling and step selling price increases that we’ve realized in ’19. But some of it is, it just goes away and becomes kind of a growth headwind. So, net net, I think we pretty much said high single digits units and a couple of hundred basis points of growth. So, circa 10%.

    Joseph C. PapaChairman of the Board and Chief Executive Officer

    On the second part of your question on Significant Seven, the way we look that is, if you go back historically, in 2018, early 2018, we identified seven products that we felt were the key growth drivers for us and as we thought about that, we had great success. This year, it was up 68%, achieved $269 million and expect to see it continue to grow, to be clear going forward. But what we felt is that, that’s going to leave out some really important growth drivers, like Xifaxan, like Trulance, like Thermax, like Biotrue, ULTRA, PreserVision, enVista, Aplenzin and we really came up with a group of not seven, but actually I could be fair, say, so closer to 15 products that are clear drivers for our future.

    Now, we’re not going to comment specifically about those, but my point was that, there are some big opportunities there for for the future relative to where we saw the future of this business and specifically you get a product like Xifaxan, our largest product growing double digits, really is a meaningful contributor and you can’t leave that out of the equation as you’re thinking about the future for our business. So, that was really the issue. It was — no concerns about our expectations for the future on that one.

    Chris Schott? Next question?

    Operator

    The next question comes from Chris Schott of JPMorgan. Please go ahead.

    Chris SchottJPMorgan — Analyst

    Great, thanks very much. Maybe, first question was — maybe one for Paul, and just following up with the potential for a split and some of those comments you made investor appetite for pure plays. You mentioned that’s a trend to think about down the road, but just maybe a little more color on what you’d need to see to enable a split. Is this simply just a matter of getting leverage to a lower level or is there something fundamentally we need to think about in the businesses before you would consider maybe separating out into individual kind of units as compared to the portfolio you have today.

    My second question, which is a quick one on the second Xifaxan filer. Just any color about this filer relative to Sandoz as you think about the defense of that franchise over time? Thanks very much.

    Paul S. HerendeenExecutive Vice President and Chief Financial Officer

    Yeah, Chris. Thanks for the question. I’ll, obviously take the first one. Yeah, leverage — I would say, our level of leverage today is a — makes it — would make it challenging to pursue something where we spin out one of our entities or whatever. It’s not impossible, but it would make it a fairly significant challenge. That is the primary thing that we’d sit there and say, it becomes more clear for us with the passage of time. And yeah, I don’t think I’m saying anything here that’s groundbreaking. Pure play is a thing. I mean people pure play. We get it. We own businesses that are very attractive and very attractive in their own right, as we’re sitting here today, and for the near term and we continue to believe that we are based on our cap structure stronger together and we’ll continue to evaluate opportunities for providing that pure play as we go forward.

    Joseph C. PapaChairman of the Board and Chief Executive Officer

    On the second part of your question, the new Xifaxan filer, as I mentioned in my comments, that company is Norwich. My understanding, although we don’t have all the information yet, is they filed specifically on both the IBS-D and HE. Our belief is that we have 23 patents. So, when we initially settled with the largest generic company Teva, we had 22 patents. We have now supplemented that with another patent. So, we have 23 patents. So, we feel very strong about our intellectual property position, relative to this filing and we don’t see anything specifically different from this — from what they filed versus what Teva filed. So, we continue to believe we’ve got a strong intellectual property position. So, no other specifics or any differences that we’ve observed.

    Operator, I have time for one more question, please.

    Operator

    The last question comes from Akash Tewari of Wolfe Research.

    Akash TewariWolfe Research — Analyst

    Hey, guys. Thanks so much. So, look, if we take into account the $275 million LOE impact, the roughly $160 million kind of inventory true-up accrual benefit you had in 2019 that might not necessarily carry over. It looks like you need over $500 million in new product sales year-over-year to kind of hit the midpoint of your guidance on reps. Can you walk us through where that growth is coming from? I’m assuming maybe like a $150 million is on Xifaxan, but what’s the contribution on the Significant Seven, what’s the contribution on Thermage etc., etc. Any color would be really appreciated.

    And then, just a bit on the cash flow, there was a bit of dip in Q4. I’d love a bit more color on what happened and then how we should think about it in 2020. It looks like your 2020 cash flow from operations is $1.5 billion, which is a bit lower than what I had expected. So, if there is any color on that, we’d really appreciate it. Thanks.

    Joseph C. PapaChairman of the Board and Chief Executive Officer

    Okay. I’m going to start, but Paul, we’re going to — there is a quite a few questions. We’re going to have to take pieces here. I think the fundamental first question is, where can we grow and how can we grow in 2020 and beyond and what I would simply go back to is that, as we look at our business, we think the overall B&L International business is going to grow at that mid-single-digit rate. I think your characterization of Xifaxan growing ballpark 10%. I think that’s a fair characterization. Solta, I think, you saw the growth that we experienced with Solta in 2019. We clearly think that that’s a great opportunity. And then, the final area I’d say is the derm returning to growth is a really important message. If you think about our business, the B&L business, the Salix business have been important to us, but we’ve had a headwind with dermatology as that dermatology grows, especially, with some of the new programs — new products like Duobrii plus the derm.com — dermatology.com contribution to our business, we think, are all going to be important parts of that growth for the future and obviously we got less LOEs versus we had in the past, but, Paul, anything you want to add to that portion or talk a little bit about cash flow with it.

    Paul S. HerendeenExecutive Vice President and Chief Financial Officer

    Well, sure. I mean, I actually — I do want to talk about the kind of the growth and where is it going to come from. First is, I think you stated a number of — on the kind of an inventory issue that was we are well above what it really was. In 2019 V ’18, the aggregate amount that it was kind of an one-timer if you will, of us taking those wholesale inventories down, was $76 million. Big number in the quarter, a couple of hundred basis points of volume growth that was based on that relative — basically what was a relative expansion, although was — we are not in expansion at all. And for the year, yeah, it was also baked into our year versus 2018, but not as big a factor on a total revenue base of $8.6 billion odd (Phonetic). If you look at the bridge on Slide 11 of our presentation, that $415 million of increase coming off from what we call base performance is obviously net of any pipeline things that that would have come up. So, that bridge shows you, I think, how we will get to — in the aggregate at a companywide basis, how we’ll get to within our revenue guidance.

    With respect to cash flow, I mean, I don’t want to start (Phonetic) with 2019 because as I said on my prepared remarks, we were at $1.501 billion. So just at the low end of our guidance range and to be superclear, that is for cash generated from operations and that’s on a GAAP basis. The primary difference between us — it being $1.5 billion and being $1.55 billion or $1.6 billion was that we did at the end of the year have more inventory than we had perhaps been thinking about when we started the year and that was based on specific decisions that we took to increase inventories of both finished goods and API for key products to ensure that we had consistency of supply. You’ll get our balance sheet later this year. You’ll see the increase in our inventory at the end of the year and that was a primary driver.

    Looking ahead to 2020, we have all the factoids that you essentially need to make a — come up with a forecast for cash flow from ops. You got our adjusted EBITDA from the guidance range, you’ve got our interest expense. You’ve got restructuring and other. You’ve got milestones and license agreements. You have a pretty good idea of what our taxes will be based on our guidance there and the one wildcard is working capital. We will grow in 2020 V 2019 and accordingly, that growth if you assume we are currently at the right level of adjusted working capital, which I would comment on in a minute that you would add to working capital. So, you’ll do that math, and you’re going to come out somewhere near $1.5 billion. That’s the way the math works out. I mean the pieces that you can’t see or can’t forecast as well as we can, is the interaction, or the impact of accruals and other things that are very difficult to forecast, but I think the $1.5 billion will be consistent. I mean, interesting if you look at the history, in 2018, it was $1.501 billion and in ’20 — ’19, it was $1.501 billion and we’re guiding to a $1.5 billion in 2020. It’s what we expect today. It could be more than that, but we are — we’ll just have to wait and see how that year plays out.

    On my last comment, I said about inventory and working capital. I want to — do provide additional texture. Over time, we are going to drive our inventory balance down. We made some progress and we’ve now taken some strategic steps that have moved us in the opposite direction. Longer term, we will be able to unlock cash from our balance sheet by better managing our inventory balances. We’re not seeing it in 2019 and I am essentially telling you, we’re not going to see it in a significant way in 2020.

    Joseph C. PapaChairman of the Board and Chief Executive Officer

    Stop there. Okay. Let me just thank everyone for joining us and we’ll see you soon as we will be on the road for the next few months at the various healthcare conference. Thank you everyone for joining. Have a great day, everyone.

    Operator

    (Operator Closing Remarks)

    Duration: 64 minutes

    Call participants:

    Arthur J. ShannonSenior Vice President and Head of Investor Relations and Communications

    Joseph C. PapaChairman of the Board and Chief Executive Officer

    Paul S. HerendeenExecutive Vice President and Chief Financial Officer

    Terence FlynnGoldman Sachs — Analyst

    David AmsellemPiper Sandler — Analyst

    Ken CacciatoreCowen & Company — Analyst

    Umer RaffatEvercore — Analyst

    Greg FraserSunTrust — Analyst

    Jason GerberryBank of America — Analyst

    Chris SchottJPMorgan — Analyst

    Akash TewariWolfe Research — Analyst

    More BHC analysis

    All earnings call transcripts


    AlphaStreet Logo

    Psorilax:A buon prezzo online |crema per psoriasi pustolosa

    0

    Psorilax: prezzo, funziona, recensioni, opinioni, ingredienti

    On Oct. 8, Anelise Dao posted a picture to Instagram of herself smiling in the sunshine. She’s wearing a black crop top, and her purple ombré floats to her left shoulder. Intricate black tattoos and long pink nails decorate her fingers, which hold a delicate white rose. At first glance, she could be at Coachella.

    But below the smile, the shirt, the nails, and the rose, several large white bandages cover Dao’s stomach. A feeding tube protrudes above her navel. Her bracelets are a mix of dangling silver charms and white hospital bands.

    “I am beautiful,” she wrote, “Lines, tubes, scars and all.”

    The post, a mashup of the bleak reality of illness and the motivational conventions of Instagram, nails the aesthetic of social media’s latest conquerer: the chronic illness influencer.

    Instagram and YouTube accounts dedicated to long-term medical conditions are gaining hundreds of thousands of followers. They share grim, and sometimes glamorous, pictures from the hospital, detailed health confessionals, and words of inspiration.

    Instagram users have tagged posts with #chronicillness 2.6 million times. YouTube videos from patients about changing feeding tubes rack up millions of views. Hospital-bed snapshots like Dao’s accrue thousands of likes.

    The explosion reflects an increase in chronic illness. The majority of people in the United States—60 percent, according to the U.S. Centers for Disease Control—now suffer from one such sickness, up from 50 percent a decade ago. Just under half the population has been diagnosed with multiple conditions. Ongoing illnesses already account for the majority of health care spending across the globe, and the World Health Organization expects that to grow exponentially in the years to come.

    As more people are getting sick, they’re talking about it more often online, especially on Instagram and YouTube. They’re finding community, followings, business opportunities—and skeptics and trolls.

    Influencers say the chronic illness community—“spoonies,” as they refer to themselves—has grown massively in the past three years.

    “I didn’t know what the term ‘chronic illness’ or ‘invisible illness’ meant before 2016,” said Jameisha Prescod, who runs @youlookokaytome (9,680 followers). In mid-December, she wrote an Instagram post about meeting a fellow lupus sufferer: “Do you remember the first time you spoke to someone else with the same chronic illness as you?… It’s so hard to explain. It’s almost euphoric.”

    I didn’t know what the term ‘chronic illness’ or ‘invisible illness’ meant before 2016.

    Jameisha Prescod

    Kassandra Shore writes about Ehlers-Danlos Syndrome, a group of disorders that produce defects in the body’s connective tissues, at @just.my.genes (4,700 followers). She said she started her Instagram page as a way to update friends and family on her condition last July after a major surgery. Well-meaning relatives couldn’t understand why she would seem fine at a party but need to go to the hospital so often. The fear of publicizing such an intimate journey kept her from opening the account to the public for months. When she did, fellow EDS patients started messaging her, and her following grew.

    Shore posted a collage of her most-liked photos from 2019 in late December. All but one showed her in a hospital—standing beside an IV pole, in a hospital bed intubated after surgery, or close to the camera with half a dozen tubes curving into her chest.

    “This is so fascinating to me bc all but one picture is of me at my worst possible health. This year has kicked my butt so much and I don’t share everything,” she captioned the display. She went on to give details about the difficulties the last year had posed, particularly an open heart surgery.

    Dozens of commenters poured forth with support and their own experiences. “❤️✊🏼i had the hardest in every way year whit (sic) my daughter who has cf (cystic fibrosis),” one wrote. Another: “Here’s to a better 2020. You are an inspiration to me in how you have handled everything.”

    Other pages like the Chronic Love Club (@chronicloveclub, 33,600 followers) take submissions from followers and post them to showcase different experiences. Sick Sad Girlz Club (@sicksadgirlz, 7,650 followers), a similar account, featured Lena Dunham talking about her obsessive compulsive disorder, endometriosis, EDS, fibromyalgia, and chronic Lyme in April 2019 (“I have never been well,” she wrote).

    Some pages share memes about the struggle (“Me: I’m exhausted. Fitbit: You’ve taken 11 steps today”) and tranquil inspiration (“You can do everything right and still have a flare up”) as palliatives to the daily frustrations and anxieties of sickness. There’s no shortage of medical advice.

    Melody O’Lander, who started @butyoudontlooksickofficial (4,795 followers) in October to talk about chronic inflammatory demyelinating polyneuropathy (CIDP), said her followers will often ask if she knows anyone knowledgeable about their conditions. Their doctors often don’t believe they’re sick with anything beyond anxiety, she said, so they turn to the internet for solidarity.

    “My page connects people with the same diseases. If there are 15 people I find with EDS I’ll put them into a group DM. People have gotten more definite diagnoses or known what tests to run because of the group, and they end up more educated and advocating for themselves more,” O’Lander said.

    Many of the influencers say they have conditions that are rare, have no outward manifestation, or have been dismissed as a true illness by some in the medical establishment.

    And O’Lander said she started her page, in part, to reach skeptics. “People are suffering from illness, but other people only see the benefits: a plaque, taking a test later. We’re trying to share the reality of it—the tubes and the day-to-day,” she said.

    But not everyone believes that reality is, well, real.

    Dao’s midriff-baring photo got 1,000 likes, but her posts don’t always receive such a warm reception.

    Members of the 26,000-member Reddit forum r/IllnessFakers are doubtful the 20-year-old Illinois State University student and model—and other very public members of the chronic illness community—are sick at all. Their posts are full of claims about influencers they know only from the internet. “She pulls out tubes and gives herself infections,” one wrote of Dao in mid-November, citing no evidence. “Her goal seems to be sepsis.”

    The Redditors criticized Dao for bragging about her father’s purchase of three cars in 2019 while she simultaneously promoted an Amazon wishlist so Instagram followers could buy her gifts. Another post on the forum speculated she sent an anonymous rude message to herself so she could clap back and solicit pity. Dao, who says she suffers from a range of conditions including gastroparesis and uses feeding tubes, declined to be interviewed. She’s previously called the Reddit posts “doxxing,” threatened police action, and indicated the public dissection of her medical status has taken a severe toll.

    “I don’t know what the fuck I did. Why do you guys hate me so much?” she asked in a Jan. 3 Instagram story. “I can’t take the bullying any more—the Reddit, the mean comments… Are you guys trying to push someone to suicide? Because that’s exactly where this is going to go if this continues.”

    On Feb. 15, Dao cleared her Instagram but for a single post: herself in a plain white dress saying goodbye. She told her 10,100 Instagram followers that the hate she received—skeptics ridiculing her every move, making memes about her, brigading her Instagram comments, contacting her doctors, messaging her family, calling 911 on her—had ruined her mental health. She plans to delete her account soon.

    “Thank you to everyone who’s been on my side and been my friend. I hope someday I can return, as of now it doesn’t look like I can stay in this community,” she wrote. “It’s been a good run!”

    She may not have truly cured herself of Instagram, though. When one fan asked if they could continue following her somewhere new, she said, “Yes I have a private Instagram.”

    The Reddit forum’s description says its goal is to “address the fact that people who feign, exaggerate or even induce medical symptoms, conditions and complications do exist and, directly or indirectly, they are hurting the chronic illness community at large.”

    In essence, they see themselves as digital police officers, on the lookout for examples of what University of Alabama clinical psychiatry professor Dr. Marc Feldman calls “Munchausen by internet.” The forum cites Feldman’s research as inspiration.

    “The internet offers ‘virtual support groups’ through formats such as chat rooms and newsgroups,” Feldman wrote in a 2000 paper, long before “influencer” was an actual job description.

    “However, individuals may misuse these internet groups at times, offering false stories of personal illness or crisis for reasons such as garnering attention, mobilizing sympathy, acting out anger, or controlling others.”

    Feldman told The Daily Beast that faking an illness can provide the approval and encouragement some people crave but don’t get from friends and family—and it can also create an identity for those who lack a clear sense of self.

    “Claiming to be a patient, and a terribly complex and sickly one at that, instantly gives a definition: ‘That’s what I am. I’m a chronically ill patient with a legion of followers,’” he said.

    Feldman has a medical degree and a long history of studying factitious disorders. The credentials and motives of the Redditors on r/IllnessFakers are far murkier. The moderators declined to be interviewed on the record.

    The first IllnessFakers’ post appeared in February 2018 after the internet gossip forum Lolcow (named for the internet slang term for a fun target of ridicule) discontinued “Munchie” threads that discussed alleged cases of Munchausen Syndrome.

    The first poster said that he himself was a patient: “I’ll need one or two other moderators because ironically I’m too ill to keep up with this myself should it take off.” He ended with a first commandment: “Play nicely.”

    He later deleted his account, but the forum did, in fact, take off. These days, its members spend countless hours scrutinizing “spoonie” posts and crafting highly detailed briefs on why they think one or another is fabricating, exaggerating, or imagining a sickness.

    One influencer’s recent grid of her most popular posts, all showing her in the hospital or wearing a breathing mask, drew particular scorn: “Last years top 9—notice a pattern? No wonder some of them keep this up,” one Redditor wrote. Another commented, “You know I’ve never ever seen (her) post a picture of herself with stretchy skin. That would prove without a doubt that she has EDS.”

    The forum erupted in April after the death of Jacqueline Beckwith, a 23-year-old from Florida who was known to her 140,000 YouTube subscribers as Chronically Jaquie. Beckwith, who claimed to have a super-rare mitochondrial mutation that caused more than half a dozen illnesses, was a favorite subject on IllnessFakers. After she died, the Reddit responses were simultaneously mournful and scornful.

    “It’s surreal, after following (Beckwith) for years knowing she was OTT (over-the-top) and faking, seeing all of it. I’m so sad she passed, especially as it was so unnecessary,” one post read.

    Members found renewed purpose in her death. One said, “I’m absolutely devastated by this. This is the danger. A girl has died in her pursuit of illness. This is what this sub(reddit) is about.” Moderators were forced to ask members to stop posting videos from her funeral.

    One member wrote that Beckwith’s videos had helped him reach a successful diagnosis, but he still accused the YouTuber of exaggerating the severity of her postural orthostatic tachycardia syndrome (POTS), a blood-pressure disease which causes extreme lightheadedness when sitting or standing up, and her Ehlers-Danlos Syndrome.

    “She is the reason I was diagnosed with several of my illnesses and I’m grateful for that, but I’m also not going to ignore that she chose the most invasive/complicated/dangerous treatment for each of her illnesses,” the post read.

    Other forums that are obsessed with illness influencers also analyzed Beckwith’s death like it was a cold case to solve. Members of the longstanding internet drama discussion site Kiwi Farms even speculated she’d faked her death.

    The Redditors and fellow skeptics point fingers with an air of authority. But how can they diagnose fakery purely by examining someone’s social media posts?

    Feldman, the psychiatrist, thinks it’s possible. His paper describing online medical catfishing details 10 warning signs of fraud, including a cycle of near-fatal flares and seemingly miraculous recoveries, a disregard for the seriousness of those crises, dummy social media accounts, posts that are too long for someone in the throes of severe illness, and resistance to phone or in-person contact. He said online fraudsters will often accuse their own support groups of providing inadequate support, whipping up more drama.

    “Deception is so easy now compared to before social media,” he said. “People had to study up in university textbooks, go to the library, and fake dramatic symptoms like seizures and coughing up blood in person to convince physicians,” he said.

    “Now you can just stay in your pajamas and check Wikipedia for even an esoteric medical ailment and go to any of the thousands of support groups out there. If your initial deception isn’t successful, you go elsewhere on the internet.”

    At least one person has reported IllnessFakers to Reddit for harassment, but it remains active. Moderators have written into the forum’s rules that they condemn harassment and prohibit posting a target’s personal information, like a home address or a phone number. The forum only allows discussion by pre-approved members, though how someone qualifies is unclear.

    “We are NOT here to simply bash spoonies,” moderators wrote. “We are here to call out those who are either overtly faking outright, or exaggerating their problems in such an over-the-top and extreme way that it makes the whole community look bad and silences the voices of those who don’t have the most followers or feel they cannot speak because they don’t have a port or wheelchair or whatever.”

    The doubters infuriate advocates for the chronically ill, who say they already struggle to convince their doctors that their symptoms are real. Prescod thinks they are motivated by self-hatred.

    “Most of the people who are on (r/IllnessFakers) are people who are sick,” she said. “They’ll say, ‘I have this, and this other person on Instagram definitely doesn’t.’ I think it’s sad. I assumed at first it was people who were well. Everyone presents differently.”

    Nevertheless, she and other high-profile spoonies live in dread of being called out on the forum. “I tend to get scared that I’ll be on there one day,” Prescod admitted.

    Shore said she actually crafts her Instagram posts with the forum in mind, making sure there’s no room to question whether she’s truly unwell.

    “I share just enough to ‘prove’ that this stuff is legitimate. Sharing videos and sharing photos of things as they happen can be helpful. I don’t share my doctors’ names or medication names,” she said. “What’s complicated about chronic illness is that you can be sick one day and be fine in the next couple days.”

    In the war between the spoonies and the skeptics, the influencers seem to be winning so far, buoyed by their growing numbers and greater social acceptance of illness—possibly fueled by celebrities talking about their own health struggles with Lyme disease, endometriosis, and autoimmune diseases.

    Even corporations are getting in on the action. Nitika Chopra (@nitikachopra, 41,800 followers) has worked with Tide and Dove on sponsored Instagram posts this year. CVS advertised a giveaway on another influencer’s page in August, as did a trendy breathing mask. Some influencers told The Daily Beast they’ll promote the Mighty Pack, a backpack for feeding tubes and other medical equipment, pro bono or in exchange for a pack.

    In 2018, Chopra founded Chronicon, a convention for people with chronic illnesses; $150 tickets for the first one, in late October in New York City, sold out three weeks in advance, she said. Panel discussions included topics like “Am I Sick Enough?” and “Chronically Capable of Love” and “The Business of Being You,” which instructed listeners on how to build a following by sharing stories of your chronic illness and monetizing that audience.

    “I felt like I was the only person who had psoriasis or psoriatic arthritis, which isn’t true, but every time I met someone else who had it, they felt the same way. Why is that the case?” she told The Daily Beast.

    Chopra, a beauty blogger and former talk show host, geared the event towards a younger, Instagram-savvy crowd. The event’s website was awash in millennial pink, as were the name cards emblazoned with the slogan “Breaking the cycle of isolation.” Attendees could partake in hair health consultations and load up their plates under a banner reading “Fight the good fight with good food.”

    Speakers’ titles ranged from “board certified OBGYN” to “wellpreneur + teacher.” Former What Not To Wear host Stacy London gave the keynote, calling the event “the community I’ve always hoped for.” A “Chronically Conscious Celebration”—also known as a party—followed. The media company Healthline sponsored the event, and Chopra said Chronicon turned talking about her health into a full-time job.

    Ardra Shephard, a blogger and Instagrammer (@MS_trippingonair, 7,000 followers) who writes about her battle with multiple sclerosis, has inked a deal for a show based on her material with the Canadian production studio Shaftesbury, she told The Daily Beast. Since she went public four years ago, blogging and social media have become her livelihood, she said. WebMD made a short film about her, “Tripping On Air: My Trip Through Life With MS”. She also sells merchandise, though she said revenue from it was minimal.

    Shephard believes the movement will only grow.

    “We don’t see those stories of young people with chronic illness in media,” she said. “We still leave out disability in inclusion. It’s the next big social justice movement.”

    It’s the next big social justice movement.

    Ardra Shephard

    Peer-reviewed studies have shown that support groups help chronic illness patients rely less on their doctors and increase their activity levels, and researchers at the National Institute of Health observed that some doctors found social media an effective tool for working with chronic patients on self-management of their own illnesses.

    But there’s no guarantee that connecting with fellow sufferers will be good for someone.

    The Mayo Clinic warns that patients gathering in support groups may exacerbate each other’s symptoms if they fall prey to “conversations dominated by griping,” “inappropriate or unsound medical advice,” or “competitive comparisons of whose condition or experience is worse.” The online analogue poses similar risks. Writers have described how joining Facebook groups dedicated to chronic illnesses held their focus hostage to the worst possible outcomes that others had suffered.

    The American Chronic Pain Association (ACPA) runs support groups across the country. There’s no online component to them at all, said founder and CEO Penney Cowan. “You don’t have the same amount of control in an online group as you do in person,” she told The Daily Beast.

    Cowan said talking about physical symptoms during ACPA support group sessions is prohibited in order to redirect participants’ attention to the things they can control and empower them.

    Dr. David Stukus, a pediatric allergist with Nationwide Children’s Hospital in Columbus, Ohio, has seen his patients benefit from online communities.

    “If you can find others out there that know what it’s like to go through what you’re going through, that’s extremely powerful, and there is a lot of benefit in the emotional support patients get and in tips for daily living that they’re not going to get from your doctor,” he said.

    “That said, nobody should be giving out individual specific medical advice online, period,” he cautioned. “Whether you’re a qualified doctor, patient, or anybody else, there are too many important nuances that can influence somebody’s care management that you can’t get from a direct message or a Facebook group.”

    Stukus—who corrects false and exaggerated health claims through his Twitter and Instagram accounts—agrees that influencers can hold outsize sway over struggling followers.

    “It’s a lot easier to trust somebody who tells an emotional story as opposed to somebody who’s spouting science in a professional way that maybe doesn’t relate to people,” Stukus said. “But somebody’s personal anecdote is really just their own story, and it may have no bearing whatsoever on anybody else in this world.”

    Feldman thinks the potential for misinformation is great. That’s why, even though he has never even visited Reddit, he believes a forum like IllnessFakers is a net benefit to society.

    “The stuff in real life, the doxxing—that I would have much more trouble with,” he said. “You want to confront the behavior, you don’t want to destroy a person’s life or stalk them. If you do, you want to ask yourself why this has become such a powerful mission.”

    But, he added, “it seems like the number of vague ailments that people are reporting is increasing so massively that it’s actually a public service to nip these in the bud.

    “Some make no medical sense—after decades of medical intervention, they never get better, and a cause is never found. Yet despite chronic fatigue syndrome, people still manage to fly across the world and give talks and write books. They seem to have enviable energy.”

    That kind of comment angers the influencers, who say they are constantly grappling with the tension between appearance and reality. Are they obligated to perform their illnesses? Does looking beautiful in a selfie mean you’re not sick?

    “I parked in a handicapped spot two weeks after one of my major spine surgeries, and a woman and her husband yelled at me that I should be ashamed of myself,” Shore said.

    “Part of what people like about these Instagram accounts is that they can see someone on a train sitting in handicapped spot, and previously they would have said, ‘Oh, they’re young. They don’t deserve to sit there,’” she added.

    “But the more they see of us, the more they understand you can look totally OK on the outside and still have health issues that are very limiting.”

    Editor’s note: Ehlers-Danlos Syndrome weakens the body’s connective tissues. A previous version of this story misstated its symptoms. Ardra Shephard has reached a TV deal with Shaftesbury. A previous version of this story misidentified the studio. We regret the errors.

    Psorilax:a che serve |crema per psoriasi therma

    0

    Psorilax: prezzo, funziona, recensioni, opinioni, ingredienti

    Mighty Patch crea adesivi che aspirano tutto il sudiciume dai pori come una calamita, senza rompere la pelle.

    didascalia
    Mighty Patch crea adesivi che aspirano tutto il sudiciume dai pori come una calamita, senza rompere la pelle.
    fonte
    Hero Cosmetics
    • Non devi spendere una fortuna per ottenere ottimi prodotti per la cura della pelle che funzionano.
    • Ho chiesto al team dello shopping Insider di condividere i loro prodotti per la cura della pelle preferiti di sempre per combattere l'acne – il tutto a meno di $ 25.
    • Ancora a caccia? Puoi trovare i nostri 16 marchi di cura della pelle preferiti da acquistare qui.

    La cura della pelle può essere un argomento delicato. Ognuno ha preoccupazioni diverse, ma alla fine tutti abbiamo lo stesso obiettivo di sentirci e apparire belli nella nostra pelle.

    La verità è che, nonostante tutte le riviste e i siti web ti dicano il contrario, non è necessario spendere centinaia di dollari per la cura della pelle per vedere i risultati. A volte è più semplice (ed economico) davvero meglio.

    Ho chiesto ai miei colleghi di condividere i prodotti per la cura della pelle abbordabili che usano e amano, perché chi meglio di ricevere consigli da un gruppo esigente di revisori dei prodotti?

    Di seguito troverai 25 prodotti per la cura della pelle a meno di $ 25 che il team di acquisti Insider giura.


    Salviette detergenti semplici per il viso

    fonte
    Amazon

    $ 4,46, disponibile su Target e Walmart

    Il passo più importante nella prevenzione dell'acne (se almeno me lo chiedi) è rimuovere trucco, sporco e sporcizia dai pori prima di andare a letto. Personalmente trovo che queste salviette per il trucco siano le migliori per il lavoro, ma a volte uso anche l'acqua micellare Simple e un dischetto di cotone riutilizzabile se ho un po 'più di tempo. Le salviette sono semplicemente super convenienti. – Sally Kaplan, senior editor


    Lozione tampone Mario Badescu

    fonte
    Ulta

    $ 19, disponibile a Ulta, Sephora e Nordstrom

    Per l'acne cistica che si presenta ogni mese, userò questo liquido resistente. È molto acquoso, quindi devo stratificarlo quasi come un siero, ma mi aiuta a liberarmi dai dossi rossi arrabbiati più velocemente e meglio della Lozione Essiccante del marchio; Trovo che la Lozione Essiccante sia migliore per i punti bianchi. – Jada Wong, senior editor


    Unguento antibiotico originale di neosporina

    fonte
    Walmart

    $ 6,97, disponibile su Walmart, Target e Amazon

    Per i punti bianchi che scelgo (scusate tutti i derm che ho amato prima …), provo a curarlo con un po 'di neosporina. A questo punto, quella whitehead è diventata una lesione aperta, quindi un unguento antibiotico aiuta ad accelerare il processo di guarigione. – Jada Wong, senior editor

    Uso questo trucco dal liceo, ed è ancora il mezzo più veloce ed efficace che ho trovato per le imperfezioni di guarigione che ho riscontrato. Accelera il processo, nega totalmente la secchezza, non ostruisce i pori e mi impedisce di toccarli più e di introdurre più germi. – Mara Leighton, giornalista senior


    Detergente schiumogeno glicolico Mario Badescu

    fonte
    Ulta

    $ 16, disponibile su Ulta, Sephora e Nordstrom

    Non è tanto che ho visto i risultati passare a questo, a parte il fatto che non succede nulla con la mia faccia, nel miglior modo possibile. Quando lo uso non ho alcuna preoccupazione su come apparirà il mio viso. Qualunque cosa sia fatta, è grandiosa. – Breton Fischetti, vicepresidente del commercio


    Mighty Patch Hydrocolloid Acne Assorbente Pimple Spot Dot

    fonte
    Hero Cosmetics

    $ 12,50 per 36 patch, disponibili su Amazon

    Questa è la mia soluzione ideale per quei brufoli arrabbiati e pieni di pus che spuntano sul tuo viso nei momenti più inopportuni. Gli adesivi assorbono i liquidi cattivi dai brufoli e puoi vedere direttamente i risultati: quando togli l'adesivo il mattino successivo (o anche solo poche ore, a seconda della natura del brufolo), l'adesivo diventa bianco con il pus ha assorbito e il brufolo si è notevolmente sgonfiato.

    Dato che sono chiari, li ho persino indossati durante il giorno per lavorare, e nessuno batte un occhio. Sebbene siano più costosi della maggior parte degli altri marchi, ho scoperto che queste particolari patch sono molto più efficaci nel curare il brufolo e hanno anche aderito meglio alla pelle. – Connie Chen, giornalista senior

    La mia vita sarebbe stata drasticamente migliore al liceo se questi esistessero allora. Sono incredibili nel ridurre le dimensioni e la gravità delle imperfezioni intense durante la notte – e contrasta la mia tendenza a prenderle, che mantiene le paure di nuovi germi cattivi o di cicatrici a lungo termine fuori dall'equazione. – Mara Leighton, giornalista senior


    Detergente viso schiumogeno delicato Cetaphil

    fonte
    Bersaglio

    $ 7,99, disponibili su Target e Ulta

    Cetaphil è, letteralmente, l'unica cosa che ho messo in faccia (oltre a SPF, ovviamente). Ho una pelle molto sensibile, così spesso i lavaggi facciali amati contro l'acne mi fanno scoppiare Di Più.

    Ho usato il tradizionale detergente per il viso delicato di Cetaphil per anni, ma di recente sono passato al detergente schiumogeno delicato e ho notato immediatamente una differenza. Ho una pelle mista, quindi la mia fronte è grassa e soggetta a sfoghi, mentre il resto del mio viso è costantemente asciutto. La formula in schiuma è il perfetto equilibrio tra la lotta contro l'olio sulla mia fronte senza seccare il resto del viso. La prima volta che ho usato Gentle Foam Cleanser, mi sono svegliato sinceramente scioccato nel vedere una fronte priva di brufoli senza sentirmi stretto e asciutto. Considerando che ho messo in totale due prodotti sul mio viso, sono fiducioso che Cetaphil sia un campione per la pelle sensibile. – Emily Hein, collega della squadra di shopping


    Acqua tonificante leggera ad alta umidità Muji

    fonte
    Muji

    $ 21,99, disponibile su Amazon

    La mia faccia sembrerebbe un esoscheletro se non fosse per questo toner estremamente idratante. La linea skincare di Muji è l'eroe sconosciuto del marchio, ma scriverei un intero musical su questo prodotto se avessi l'energia creativa. È estremamente idratante, delicato sulla pelle sensibile e funge anche da toner e idratante, particolarmente utile durante l'estate quando si desidera solo uno strato sottile e leggero di prodotto sul viso. – Sally Kaplan, senior editor


    Maschera da nuvola in cotone Saturday Skin

    fonte
    Sephora

    $ 6, disponibile da Sephora

    Le maschere per il viso sono un modo divertente e conveniente per trattare la tua pelle quando ha bisogno di una piccola spinta. Di recente ho provato questa maschera per il sabato Skin Skin e ha fatto miracoli per la mia pelle jet-lag. Oltre all'adorabile confezione, questa maschera super-idratante è ricca di prebiotici e probiotici per dare alla tua pelle una forte idratazione e luminosità. – Remi Rosmarin, giornalista


    Lozione Essiccante Mario Badescu

    fonte
    Mario Badescu

    $ 17, disponibile su Amazon, Ulta e Sephora

    La lozione essiccante di Mario Badescu è magica. È un trattamento per l'acne che asciuga i punti bianchi mentre dormi, quindi sono praticamente scomparsi la mattina dopo. Una bottiglia di questa roba mi dura circa sei mesi circa. – Ellen Hoffman, direttore esecutivo


    Toner all'acqua di rose Fleur & Bee

    fonte
    Fleur & Bee

    $ 18, disponibile su Amazon

    Di recente ho iniziato a utilizzare questo toner di una nuova azienda totalmente vegana perché ero stanco di affrontare la mia acne adulta. Mi piace davvero quanto sia sottile ma dolce il profumo dell'olio di fiori di rosa e che aiuta a gestire la mia pelle grassa durante il giorno. Inoltre, so esattamente cosa mi sto mettendo in faccia. – Francesca Rea, produttrice di contenuti


    Differin Adapalene Gel 0,1%

    fonte
    Amazon

    $ 12,88, disponibile su Amazon, Target e Walmart

    Differin è un retinoide che, fino a poco tempo fa, per ottenere era necessaria una prescrizione. Il mio dermatologo me lo ha raccomandato come soluzione alternativa per una prescrizione quasi identica che in genere costa $ 233. Da quando lo uso, la consistenza della mia pelle è la migliore che sia mai stata – nessun urto ruvido e irregolare. Mi ha anche aiutato a schiarire la pelle in pochi giorni durante le vacanze. È il mio trattamento topico da banco più affidabile. Puoi trovare una recensione completa qui. – Mara Leighton, giornalista senior


    Lozione idratante viso CeraVe PM

    fonte
    Amazon

    da $ 24,76 per due, disponibile su Amazon, Ulta e Target

    A volte il meglio è semplice, come nel caso di questa semplice lozione CeraVe. È leggero, ma ancora molto idratante e ha una consistenza morbida come la seta che si sente benissimo sul tuo viso. Come risultato del mio lavoro e di una vera curiosità per la cura della pelle, cerco sempre nuovi prodotti con una gamma di ingredienti diversi. Adoro avere questa lozione come mio controllo; la sua formula semplice può essere stratificata su tutto e so che posso sempre contare su di essa per una pelle costantemente morbida. – Remi Rosmarin, giornalista


    Idratante giornaliero Aveeno positivamente radiante SPF 15

    fonte
    Aveeno

    da $ 12,98, disponibile su Amazon e target

    Ho usato creme idratanti per farmacie a buon mercato, creme idratanti fantasiose che costano più di quanto sono disposto ad ammettere su Internet e tutto il resto. E devo consegnarlo ad Aveeno; questo è l'unico che ho usato costantemente dal liceo. Sono sempre sorpreso da come pochi di quei fantasiosi idratanti includano SPF, ma questo lo fa e mi sento leggero e mai grasso sulla mia pelle, il che lo rende uno dei miei go-to-go, specialmente in estate. – Ellen Hoffman, direttore esecutivo

    Come menziona Ellen, Aveeno merita davvero elogi per questo. Ho provato la mia giusta dose di creme idratanti nella vita (abbastanza per entrare nella terra di Sephora VIB solo al liceo), e mentre ho le mie costose schizzi di lozione, probabilmente non smetterò mai di immagazzinarlo nel mio mobiletto del bagno.

    Aggiunge una luminosità visibile, rende la mia pelle notevolmente più morbida e non ha mai ostruito i pori. È un po 'più costoso rispetto alle altre marche di farmacie, ma se hai intenzione di fare acquisti all'estremità più economica dello spettro, questo è il migliore che otterrai. – Mara Leighton, giornalista senior


    Tonymoly I am Real Sheet Masks

    fonte
    Tony Moly

    da $ 3, disponibile su Amazon e Ulta

    Quando sono andato a Seoul, in Corea, per la prima volta, ero una persona ignorante che non aveva mai usato una maschera per il viso o una maschera per il viso (lo so, lo so, è pazzo!). Prima di partire, ho chiesto ai miei amici cosa avrei dovuto riportare dal mio viaggio, e tutti dicevano la stessa cosa: le maschere in foglio di Tonymoly. Così andai diligentemente nell'affollato quartiere dello shopping di Seoul e vagai per il negozio di cura della pelle dopo il negozio di cura della pelle, carico di campioni gratuiti fino a quando trovai Tonymoly e comprai tre pacchetti.

    Ora uso regolarmente queste maschere di Tonymoly (specialmente in inverno) per idratare la pelle. Poiché gli ingredienti sono a base vegetale e delicati, anche queste maschere non irritano la mia pelle. – Malarie Gokey, vicedirettore


    Maschera di argilla segreta azteca

    fonte
    Segreto azteco

    $ 7,99, disponibile a Bersaglio e Amazon

    Questa maschera di argilla preferita dai cult a buon mercato è una gemma che si nasconde all'aperto. È l'argilla di bentonite al 100%, che succhia olio e sporcizia dai pori come un magnete. E, combinato con aceto di mele, restituisce alla pelle ruvida una consistenza liscia come il bambino. Nel tempo, l'esfoliazione può anche uniformare il tono della pelle. Mi ha portato in un posto dove posso andare comodamente con o senza trucco. Puoi trovare la mia recensione completa qui.

    Lo uso da cinque a 10 minuti una o due volte sul viso ogni settimana, o più frequentemente come una striscia di pori fai-da-te per il mio naso. Preferisco usarlo con l'aceto di mele piuttosto che con l'acqua, e sto attento a non lasciarlo mai più a lungo della quantità raccomandata, quindi la mia pelle non inizia a compensare la secchezza producendo più olio. – Mara Leighton, giornalista senior


    Brickell Purificante per il viso al carbone purificante per uomo

    fonte
    Brickell

    $ 25, disponibile su Amazon

    Ho usato per la prima volta Charcoal Face Wash di Brickell dopo averlo ricevuto in una Birchbox e una volta esaurito il piccolo campione, ne ho rapidamente acquistati altri. Questo è il mio detergente per il viso preferito perché, a differenza della maggior parte dei detergenti economici, non toglie l'umidità. Il carbone fa un ottimo lavoro di pulizia profonda dei miei pori e la miscela di menta piperita e oli di eucalipto dona una sensazione davvero rinfrescante e corroborante. – Amir Ismael, giornalista


    Sapone da barra Emu Noble Formula 2% Pyrithione Zinc (ZnP)

    fonte
    Formula nobile

    $ 12,99, disponibile su Amazon e Walmart

    Se vuoi che il tuo viso sia perfettamente pulito (non è affatto un'esagerazione) dopo un solo utilizzo, prova questo sapone esfoliante. Ha il 2% di zinco piritione, che ha proprietà antifungine e antibatteriche, quindi chiunque soffra di acne, eczema e dermatite seborroica può trarne beneficio. Altri ingredienti benefici includono olio d'oliva per idratare la pelle, olio di emu per combattere l'infiammazione e il gonfiore e calendula per curare la pelle secca e danneggiata.

    Lo uso da più di un mese ed è sempre rassicurante usarlo alla fine della giornata quando voglio davvero ripulire l'olio e lo sporco che si sono accumulati sul mio viso. – Connie Chen, giornalista senior

    Devo trovarlo nella frana dei prodotti su Amazon su raccomandazione del mio dermatologo. È l'unica saponetta che ho finito e successivamente sostituita nella memoria recente. È modesto, ma funziona eccezionalmente bene. Lo uso solo per il mio corpo e lo zinco piritione al 2% chiarisce mentre la farina d'avena esfolia, e l'emu e l'olio d'oliva lasciano la pelle idratata anziché spogliata. Per dirla semplicemente, fa esattamente quello che vorresti che facesse. – Mara Leighton, giornalista senior


    Siero di acido glicolico puro L´Oreal Paris Revitalift al 10%

    fonte
    L'Oreal

    $ 23,84, disponibile su Amazon

    Dopo una combinazione di viaggi, stress e troppi dessert durante le vacanze, ho sperimentato uno dei peggiori breakout che ho avuto negli anni. Ho provato tutti i miei prodotti per la cura della pelle più fantasiosi nel tentativo di chiarirlo, e mentre acceleravano il processo, non hanno fatto nulla per le macchie scure e le cicatrici che erano rimaste indietro. Dopo solo tre giorni di utilizzo di questo siero di acido glicolico, le macchie erano meno evidenti e hanno persino bloccato alcuni brufoli ormonali più recenti che stavano tentando di apparire. Le prime applicazioni pungono un po ', ma per me vale la pena tollerare i risultati. – Ashley Phillips, editrice di stile e bellezza


    Idratante viso semplice tipo a pelle con SPF 15

    fonte
    Walmart

    $ 11,54, disponibile su Sephora

    Uso l'idratante viso semplice con SPF 15 ogni giorno per proteggere la mia pelle dai raggi del sole. Proprio come qualsiasi altro prodotto Simple, non ha coloranti, profumi o sostanze chimiche strane che possono irritare la pelle. Si assorbe rapidamente nella mia pelle e non si sente mai grassa, il che è importante se sei super biondo come me (alias bianco fantasma o traslucido) e devi assolutamente indossare la protezione solare ogni giorno o rischiare un viso rosa. – Malarie Gokey, vicedirettore


    Barra di sapone per l'utilità da uomo di Shea Moisture

    fonte
    Shea Moisture

    $ 3,99, disponibile a destinazione

    Con burro di karitè, burro di cacao, burro di mango e avocado, la barra di sapone per l'umidità Shea è perfetta per pulire e aggiungere contemporaneamente l'idratazione necessaria alla mia pelle. Oltre a usarlo per l'umidità quotidiana, può essere usato per lenire le condizioni della pelle come l'eczema e la psoriasi. La parte migliore è che posso usarlo su viso, corpo e capelli. Posso persino insaponarlo come una crema da barba per una rasatura ravvicinata e non secca la pelle. – Amir Ismael, giornalista


    troppo cool per la scuola Set di maschere per crema all'uovo

    fonte
    Amazon

    $ 6, disponibile su Ulta

    Con tonnellate di benefici idratanti e illuminanti, troppo fresco per la Egg Cream Mask della scuola è uno dei miei modi preferiti per distendermi dopo una lunga giornata e contemporaneamente prendermi cura della mia pelle. La maschera sembra sciocca quando è accesa, ma fa parte del divertimento con queste cose.

    Consiglio del professionista: acquista un pacchetto di maschere da cinque fogli su Amazon per $ 24 invece di spendere $ 6 per una singola su Ulta. – Ellen Hoffman, direttore esecutivo


    Detergente viso schiumogeno semplice per pelle

    fonte
    Walmart

    $ 5,99, disponibile su Walmart e Amazon

    Ho la pelle sensibile, quindi ogni tipo di fragranza mi sconvolge immediatamente e la rende rossa. Sebbene ci siano tonnellate di detergenti naturali per il viso che costano un sacco di soldi, non è necessario acquistarli. Simple rende un eccellente detergente schiumogeno che non ha profumo artificiale, coloranti o sostanze chimiche aggressive. Usa la camomilla, che calma e ammorbidisce la pelle, la glicerina per l'idratazione e il geranio, che lascia la pelle fresca dopo la pulizia.

    La sua consistenza delicata e spumosa è perfetta o chiunque abbia la pelle sensibile e non vuole o ha bisogno di esfoliazione ogni giorno. – Malarie Gokey, vicedirettore di Insider Picks


    Olio di karitè Tea Tree Oil & Karité Elixir dopobarba per uomo

    fonte
    Shea Moisture

    $ 5,59, disponibile su Amazon

    Ho ricevuto questo dopobarba come regalo un paio di anni fa, e ora è l'unico che uso. Non unge perché è un liquido, non una crema, si asciuga molto velocemente e ti dà appena una scossa con gli oli per farti sapere che ha fatto il suo lavoro senza quella sensazione di bruciore che provi da altri prodotti dopobarba. – Breton Fischetti, vicepresidente di Insider Picks


    Sapone detergente alle alghe Mario Badescu

    fonte
    Amazon

    $ 14, disponibile su Amazon, Ulta e Sephora

    Dopo aver provato la lozione essiccante Mario Badescu, ho deciso di provare questo sapone detergente. Mi piace che non solo pulisca, ma esfolca delicatamente la mia pelle in modo non abrasivo. Odora un po 'come la bassa marea, ma ehi, ciò significa che le proprietà anti-infiammatorie dell'estratto di alga stanno funzionando. – Francesca Rea, produttrice di contenuti


    Acqua micellare Bioderma Sensibio H2O

    fonte
    Dermstore

    $ 14,90, disponibile su Amazon, Dermstore e Walmart

    Ho provato molte diverse acque micellari, ma questo classico acquisto in farmacia francese è il migliore che abbia mai usato. L'acqua è morbida, rimuove il mascara impermeabile dalle ciglia più delicatamente ed efficacemente degli altri e lascia la pelle pulita e idratata, senza lasciare residui. Per me è stato imbattuto negli ultimi due anni, nonostante la frequente competizione. – Mara Leighton, giornalista senior